

Approved



**Tanzania**  
**Country Operational Plan**  
**FY 2017**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		1,500,854		1,500,854	0	1,500,854
USAID		205,306,554		205,306,554	71,635,756	276,942,310
DOD		41,305,674		41,305,674	14,891,400	56,197,074
PC		2,313,000		2,313,000	113,000	2,426,000
HHS/CDC	2,618,750	127,215,712		129,834,462	12,909,244	142,743,706
HHS/HRSA		2,750,000		2,750,000	0	2,750,000
State/AF		300,000		300,000	0	300,000
<b>Total</b>	<b>2,618,750</b>	<b>380,691,794</b>	<b>0</b>	<b>383,310,544</b>	<b>99,549,400</b>	<b>482,859,944</b>

### Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency							On Hold Amount	Total
	State	DOD	HHS/CDC	HHS/HRSA	PC	State/AF	USAID		
CIRC		3,455,769	9,451,298				6,935,121	0	19,842,188
HBHC		1,768,895	7,659,390	600,000			1,549,096	0	11,577,381
HKID		469,541	26,022			150,000	14,685,947	0	15,331,510
HLAB		68,153	4,175,762				266,620	0	4,510,535
HMBL			838,064					0	838,064
HMIN			15,557					0	15,557
HTXD		35,016	0				70,240,750	0	70,275,766
HTXS		22,051,200	53,776,487	300,000			35,079,984	0	111,207,671
HVAB		573,900	328,200				2,016,274	0	2,918,374

Approved



HVCT		2,860,112	10,412,833				32,755,516	0	<b>46,028,461</b>
HVMS	1,500,854	1,104,894	6,481,325		2,200,000		4,733,687	0	<b>16,020,760</b>
HVOP		3,730,631	4,561,610		113,000	150,000	14,638,828	0	<b>23,194,069</b>
HVSI		123,224	5,238,800	400,000			389,651	0	<b>6,151,675</b>
HVTB		1,876,958	5,237,560				8,643,503	0	<b>15,758,021</b>
IDUP		28,010	2,275,319					0	<b>2,303,329</b>
MTCT		1,485,729	10,907,323				3,163,774	0	<b>15,556,826</b>
OHSS			3,261,735	1,050,000			5,416,861	0	<b>9,728,596</b>
PDCS		145,956	700,929				401,823	0	<b>1,248,708</b>
PDTX		1,527,686	4,486,248	400,000			4,389,119	0	<b>10,803,053</b>
	<b>1,500,854</b>	<b>41,305,674</b>	<b>129,834,462</b>	<b>2,750,000</b>	<b>2,313,000</b>	<b>300,000</b>	<b>205,306,554</b>	<b>0</b>	<b>383,310,544</b>



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	11,318,403	0
HKID	15,205,943	0
HVTB	15,633,244	0
PDCS	1,168,321	0
<b>Total Technical Area Planned Funding:</b>	<b>43,325,911</b>	<b>0</b>

#### Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	4,085,473	0
HVSI	4,340,364	0
OHSS	8,460,000	0
<b>Total Technical Area Planned Funding:</b>	<b>16,885,837</b>	<b>0</b>

#### Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	19,690,668	0
HMBL	760,000	0
HVAB	2,590,174	0
HVCT	45,618,714	0
HVOP	22,979,994	0
IDUP	2,163,553	0
MTCT	15,258,040	0
<b>Total Technical Area Planned</b>	<b>109,061,143</b>	<b>0</b>

Approved



<b>Funding:</b>		
-----------------	--	--

**Technical Area: Treatment**

<b>Budget Code</b>	<b>Budget Code Planned Amount</b>	<b>On Hold Amount</b>
HTXD	70,112,159	0
HTXS	109,898,203	0
PDTX	10,631,397	0
<b>Total Technical Area Planned Funding:</b>	<b>190,641,759</b>	<b>0</b>



## Technical Area Summary Indicators and Targets

Indicator Number	Label	2018
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,256,203
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	835,634
	By Age (Denominator): <10	0
	By Age (Denominator): 10-14	1,445
	By Age (Denominator): <15-19	15,963
	By Age (Denominator): 20-24	281,269
	By Age (Denominator): 25-49	194,992
	By Age (Denominator): 50+	64
	By Number of known positives: Unknown Age	11,621
	By Number of known positives: <10	1
	By Number of known positives: 10-14	17
	By Number of known positives: 15-19	223
	By Number of known positives: 20-24	5,587
By Number of known positives:	4,710	



	25-49	
	By Number of known positives: 50+	5
	By Number of new positives: Unknown Age	20,654
	By Number of new positives: <10	2
	By Number of new positives: 10-14	69
	By Number of new positives: 15-19	609
	By Number of new positives: 20-24	9,531
	By Number of new positives: 25-49	7,244
	By Number of new positives: 50+	0
	By Number of new negative: Unknown Age	756,947
	By Number of new negative: <10	0
	By Number of new negative: 10-14	1,227
	By Number of new negative: 15-19	14,211
	By Number of new negative: 20-24	249,369
	By Number of new negative: 25-49	170,538
	By Number of new negative: 50+	543
	By Age (Numerator): Unknown Age	753,498
	By Age (Numerator): <10	0
	By Age (Numerator): 10-14	1,312
	By Age (Numerator): 15-19	15,008
	By Age (Numerator): 20-24	186,260
	By Age (Numerator): 25-49	180,555
	By Age (Numerator): 50+	53
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5 %
	Number of HIV-positive pregnant women who received ART to reduce risk of	57,738



	mother-to-child-transmission (MTCT) during pregnancy	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,256,203
	New on ART	36,459
	Already on ART at beginning of current pregnancy	21,279
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	5,518
	Sex: Male	4,464
	Sex: Female	1,054
	Sum of Sex disaggregates	5,518
	Unknown Sex	
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	890,168
	By Age: 0-60 days	13,810
	By Age: 2 months - 9 years	829
	By Age: 10-14	429,083
	By Age: 15-19	226,640
	By Age: 20-24	127,340
	By Age: 25-29	94,254
	By Age: 30-49	3
	By Age: 50+	3
By HIV status: Number of		



	HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	849,708
	By circumcision technique: Device-based VMMC	40,040
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	12,092
	Male 10-14	
	Male 15-19	0



	Male 20-24	0
	Male 25-49	0
	Male 50+	0
	Female 10-14	
	Female 15-19	880
	Female 20-24	2,353
	Female 25-49	6,538
	Female 50+	346
	(15-19)	
	(20-24)	
	FSW	2,252
	MSM	0
	TG	0
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	234,936
	Total number of people in the target population	
	Age/sex: 10-14 Male	0
	Age/sex: 15-19 Male	547
	Age/sex: 20-24 Male	2,028
	Age/sex: 25-49 Male	255
	Age/sex: 50+ Male	0
	Age/sex: 10-14 Female	0
	Age/sex: 15-19 Female	103,784



	Age/sex: 20-24 Female	128,022
	Age/sex: 25-49 Female	301
	Age/sex: 50+ Female	0
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	127,921
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,061
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that	12,655



	are based on evidence and/or meet the minimum standards required)	
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	108,003
	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,605
	By key population type: Females who inject drugs (Female PWID)	597



	(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated	



	number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs ( Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning	



	beneficiary within the current report period	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	100 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	51,424
	Total number of registered new and relapsed TB cases, during the reporting period.	51,424
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with	



	documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	



	reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	31,732
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19,692
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of	



	registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+	



	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	14,423
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	0
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8,878
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	8,547,208
	By Test Result: Positive	411,787
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	0
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	0
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	0
	Service Delivery Point (Community) Homebased testing: 10-14, Male,	0



	Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	0
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	0
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	0
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	0
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	0
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	0
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	0
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	0
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	0
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	0
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	0
	Service Delivery Point (Community)	0



	Homebased testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	0
	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	0
	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	0
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	0
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Homebased testing: <1, Negative	
	Service Delivery Point (Community) Homebased testing: <1, Positive	
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	0
	Service Delivery Point (Community) Homebased testing: 1-9, Positive	0
	Service Delivery Point by Agg Age	0



	(Community) Homebased testing: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	0
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative	0
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive	0
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	0
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	0
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	0
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	0
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Community) by Aggregated Age: Homebased testing: Unknown Age,	0



	Male, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	17,346
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	265
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	15,891
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	275
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	683
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	93
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	197
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	14
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,376
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	166
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	438
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	63
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	3,281
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	557
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	2,047
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	386
	Service Delivery Point (Facility)	365



	Inpatient: 50+, Female, Negative	
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	20
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	273
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	12
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Inpatient: <1, Negative	1,271
	Service Delivery Point (Facility) Inpatient: <1, Positive	12
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	24,716
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	404
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	64,281
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	780
	Service Delivery Point by Agg Age	60,589



	(Facility) Inpatient: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	724
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	69,922
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	7,452
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	35,863
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	5,943
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	6
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	5
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	6,279
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	163



	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	4,824
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	117
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	9,126
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	431
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	9,955
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	352
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	19,066
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	875
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	20,543
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	714
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	52,224
	Service Delivery Point (Community) Mobile Testing: 25-49, Female,	2,413



	Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	57,283
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	1,989
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	4,500
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	201
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	4,538
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	163
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: <1, Negative	
	Service Delivery Point (Community) Mobile Testing: <1, Positive	
	Service Delivery Point (Community)	64



	Mobile Testing: 1-9, Negative	
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	0
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	93,338
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	1,769
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	77,352
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	1,369
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	333,778
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	14,943
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	334,150
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	12,912
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age(Community) Mobile Testing:	0



	Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	43,384
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1,466
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	45,455
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1,226
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	71,802
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	2,103
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	36,451
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	1,226
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	108,559
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	8,103
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	60,280
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	3,110



	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	303,590
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	42,377
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	209,402
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	21,098
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	66,435
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	8,162
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	52,198
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	7,333
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	3
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility)Other PITC: <1, Negative	7,840
	Service Delivery Point (Facility) Other PITC: <1, Positive	48



	Service Delivery Point (Facility) Other PITC: 1-9, Negative	123,487
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1,520
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	220,864
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	2,572
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	219,761
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	2,526
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	1,381,482
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	80,539
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	876,873
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	49,102
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	143
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	1
	Service Delivery Point by Agg Age	148



	(Facility) Other PITC: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	
	Service Delivery Point (Community) Other: 10-14, Female, Positive	
	Service Delivery Point (Community) Other: 10-14, Male, Negative	
	Service Delivery Point (Community) Other: 10-14, Male, Positive	
	Service Delivery Point (Community) Other: 15-19, Female, Negative	
	Service Delivery Point (Community) Other: 15-19, Female, Positive	
	Service Delivery Point (Community) Other: 15-19, Male, Negative	
	Service Delivery Point (Community) Other: 15-19, Male, Positive	
	Service Delivery Point (Community) Other: 20-24, Female, Negative	
	Service Delivery Point (Community) Other: 20-24, Female, Positive	
	Service Delivery Point (Community) Other: 20-24, Male, Negative	
	Service Delivery Point (Community) Other: 20-24, Male, Positive	
	Service Delivery Point (Community) Other: 25-49, Female, Negative	
	Service Delivery Point (Community) Other: 25-49, Female, Positive	



	Service Delivery Point (Community) Other: 25-49, Male, Negative	
	Service Delivery Point (Community) Other: 25-49, Male, Positive	
	Service Delivery Point (Community) Other: 50+, Female, Negative	
	Service Delivery Point (Community) Other: 50+, Female, Positive	
	Service Delivery Point (Community) Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: <1, Negative	
	Service Delivery Point (Community) Other: <1, Positive	
	Service Delivery Point (Community) Other: 1-9, Negative	
	Service Delivery Point (Community) Other: 1-9, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Female,	



	Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Facility)	120,895



	Pediatric : <5 Negative	
	Service Delivery Point (Facility)	1,287
	Pediatric : <5 Positive	
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	0
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	0
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
	Service Delivery Point (Facility) TB: 25-49, Female, Negative	0
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	0
	Service Delivery Point (Facility) TB: 25-49, Male, Negative	0
	Service Delivery Point (Facility) TB:	0



	25-49, Male, Positive	
	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) TB: <1, Negative	0
	Service Delivery Point (Facility) TB: <1, Positive	0
	Service Delivery Point (Facility) TB: 1-9, Negative	0
	Service Delivery Point (Facility) TB: 1-9, Positive	0
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0



	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	10,868
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	8,782
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	21,699
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	10,073
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) VMMC: <1, Negative	0
	Service Delivery Point (Facility) VMMC: <1, Positive	0
	Service Delivery Point (Facility) VMMC: 10-14, Negative	13,928
	Service Delivery Point (Facility) VMMC: 10-14, Positive	96
	Service Delivery Point (Facility) VMMC: 15-19, Negative	121,587
	Service Delivery Point (Facility) VMMC: 15-19, Positive	2,071
	Service Delivery Point (Facility)	2,422



	VMMC: 1-9, Negative	
	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
	Service Delivery Point (Facility) VMMC: 20-24, Negative	69,380
	Service Delivery Point (Facility) VMMC: 20-24, Positive	1,262
	Service Delivery Point (Facility) VMMC: 25-49, Negative	42,133
	Service Delivery Point (Facility) VMMC: 25-49, Positive	826
	Service Delivery Point (Facility) VMMC: 50+, Negative	541
	Service Delivery Point (Facility) VMMC: 50+, Positive	0
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
	Service Delivery Point (Facility) VMMC: <15, Negative	46,527
	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	938
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	203,300
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	1,209
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	0
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	0
	Service Delivery Point (Facility)	12,875



	Index: 10-14, Female, Negative	
	Service Delivery Point (Facility)	253
	Index: 10-14, Female, Positive	
	Service Delivery Point (Facility)	11,690
	Index: 10-14, Male, Negative	
	Service Delivery Point (Facility)	217
	Index: 10-14, Male, Positive	
	Service Delivery Point (Facility)	775
	Index: 15-19, Female, Negative	
	Service Delivery Point (Facility)	235
	Index: 15-19, Female, Positive	
	Service Delivery Point (Facility)	526
	Index: 15-19, Male, Negative	
	Service Delivery Point (Facility)	140
	Index: 15-19, Male, Positive	
	Service Delivery Point (Facility)	3,579
	Index: 20-24, Female, Negative	
	Service Delivery Point (Facility)	1,256
	Index: 20-24, Female, Positive	
	Service Delivery Point (Facility)	1,089
	Index: 20-24, Male, Negative	
	Service Delivery Point (Facility)	331
	Index: 20-24, Male, Positive	
	Service Delivery Point (Facility)	14,095
	Index: 25-49, Female, Negative	
	Service Delivery Point (Facility)	5,358
	Index: 25-49, Female, Positive	
	Service Delivery Point (Facility)	7,529
	Index: 25-49, Male, Negative	
	Service Delivery Point (Facility)	2,855
	Index: 25-49, Male, Positive	
	Service Delivery Point (Facility)	3,419
	Index: 50+, Female, Negative	
	Service Delivery Point (Facility)	1,294



	Index: 50+, Female, Positive	
	Service Delivery Point (Facility) Index: 50+, Male, Negative	2,889
	Service Delivery Point (Facility) Index: 50+, Male, Positive	1,124
	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Index: <1, Negative	982
	Service Delivery Point (Facility) Index: <1, Positive	10
	Service Delivery Point (Facility) Index: 1-9, Negative	19,012
	Service Delivery Point (Facility) Index: 1-9, Positive	370
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	44,999
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	518
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	36,045



	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	495
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	66,684
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	12,403
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	41,881
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	7,997
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	20
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	2
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
	By Key Population: FSW, Negative	0
	By Key Population: FSW, Positive	0
	By Key Population: MSM, Negative	0
	By Key Population: MSM, Positive	0
	By Key Population: People in prisons and other enclosed settings, Negative	0
	By Key Population: People in prisons and other enclosed	0



	settings, Positive	
	By Key Population: PWID, Negative	0
	By Key Population: PWID, Positive	0
	By Key Population: TG, Negative	0
	By Key Population: TG, Positive	0
	Service Delivery Point (Facility) Malnutrition: Negative	8,997
	Service Delivery Point (Facility) Malnutrition: Positive	102
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	9,426
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	218
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	7,260
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	169
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	6,088
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	305
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	6,661
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	248
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	12,716
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	616
	Service Delivery Point (Community)	13,715



	Index Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	498
	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	34,889
	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	1,672
	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	38,226
	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	1,402
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	2,995
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	153
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	3,001
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	123
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Index Mod: <1, Negative	



	Service Delivery Point (Community) Index Mod: <1, Positive	
	Service Delivery Point (Community) Index Mod: 1-9, Negative	102
	Service Delivery Point (Community) Index Mod: 1-9, Positive	0
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	139,785
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	2,651
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	115,911
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	2,181
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	268,912
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	13,384
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	267,525
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	12,027
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown	0



	Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) ANC: <1, Negative	0
	Service Delivery Point (Facility) ANC: <1, Positive	0
	Service Delivery Point (Facility) ANC: 10-14, Negative	50
	Service Delivery Point (Facility) ANC: 10-14, Positive	0
	Service Delivery Point (Facility) ANC: 15-19, Negative	7,366
	Service Delivery Point (Facility) ANC: 15-19, Positive	132
	Service Delivery Point (Facility) ANC: 1-9, Negative	0
	Service Delivery Point (Facility) ANC: 1-9, Positive	0
	Service Delivery Point (Facility) ANC: 20-24, Negative	12,533
	Service Delivery Point (Facility) ANC: 20-24, Positive	426
	Service Delivery Point (Facility) ANC: 25-49, Negative	32,773
	Service Delivery Point (Facility) ANC: 25-49, Positive	1,728
	Service Delivery Point (Facility) ANC: 50+, Negative	48
	Service Delivery Point (Facility)	0



	ANC: 50+, Positive	
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	84,292
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	4,080
	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	1,905
	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	763,289
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	23,592
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	277,668
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	12,469
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	
	Service Delivery Point (Facility)	



	VCT: 15-19, Male, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	
	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	
	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) VCT:	
	Service Delivery Point (Facility)	



	VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VCT: <1, Negative	
	Service Delivery Point (Facility) VCT: <1, Positive	
	Service Delivery Point (Facility) VCT: 1-9, Negative	
	Service Delivery Point (Facility) VCT: 1-9, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age,	



	Female, Positive	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	
	Service Delivery Point (Community)	



	VCT Mod: 25-49, Female, Positive	
	Service Delivery Point (Community)	
	VCT Mod: 25-49, Male, Negative	
	Service Delivery Point (Community)	
	VCT Mod: 25-49, Male, Positive	
	Service Delivery Point (Community)	
	VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community)	
	VCT Mod: 50+, Female, Positive	
	Service Delivery Point (Community)	
	VCT Mod: 50+, Male, Negative	
	Service Delivery Point (Community)	
	VCT Mod: 50+, Male, Positive	
	Service Delivery Point (Community)	
	VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community)	
	VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community)	
	VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community)	
	VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community)	
	VCT Mod: <1, Negative	
	Service Delivery Point (Community)	
	VCT Mod: <1, Positive	
	Service Delivery Point (Community)	
	VCT Mod: 1-9, Negative	
	Service Delivery Point (Community)	
	VCT Mod: 1-9, Positive	
	Service Delivery Point by Agg Age	



	(Community) VCT Mod: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	0



GEND_GBV_DSD	Number of people receiving post-GBV care	157,638
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	69,871
	By type of service: Sexual Violence (Post-Rape Care)	74,164
	By PEP service provision (related to sexual violence services provided)	18,428
	<10, Female, Physical and/or Emotional Violence	4,243
	<10, Female, Sexual Violence (Post-Rape Care)	6,422
	<10, Male, Physical and/or Emotional Violence	2,049
	<10, Male, Sexual Violence (Post-Rape Care)	1,444
	10-14, Female, Physical and/or Emotional Violence	3,666
	10-14, Female, Sexual Violence (Post-Rape Care)	7,189
	10-14, Male, Physical and/or Emotional Violence	2,966
	10-14, Male, Sexual Violence (Post-Rape Care)	1,870
	15-19, Female, Physical and/or Emotional Violence	2,128
	15-19, Female, Sexual Violence (Post-Rape Care)	8,979
	15-19, Male, Physical and/or Emotional Violence	1,922
	15-19, Male, Sexual Violence (Post-Rape Care)	811



	20-24, Female, Physical and/or Emotional Violence	3,260
	20-24, Female, Sexual Violence (Post-Rape Care)	3,431
	20-24, Male, Physical and/or Emotional Violence	1,602
	20-24, Male, Sexual Violence (Post-Rape Care)	542
	25-49, Female, Physical and/or Emotional Violence	10,601
	25-49, Female, Sexual Violence (Post-Rape Care)	3,340
	25-49, Male, Physical and/or Emotional Violence	6,220
	25-49, Male, Sexual Violence (Post-Rape Care)	1,298
	50+, Female, Physical and/or Emotional Violence	2,074
	50+, Female, Sexual Violence (Post-Rape Care)	1,199
	50+, Male, Physical and/or Emotional Violence	1,888
	50+, Male, Sexual Violence (Post-Rape Care)	234
	Unknown Age, Female, Physical and/or Emotional Violence	19
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	585
	Unknown Age, Male, Physical and/or Emotional Violence	21
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	138
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs	811,639



	for children and families affected by HIV/AIDS	
	Age/Sex: 10-14 Male	70,604
	Age/Sex: 15-17 Male	33,559
	By: Age/sex: Male 18-24	27,465
	By: Age/sex: Male 25+	83,297
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	70,510
	Age/Sex: 15-17 Female	60,473
	By: Age/sex: 18-24 Female	45,369
	By: Age/sex: 25+ Female	81,531
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	235,146
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	8,000
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	9,229
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	6,023
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
	Required only for DREAMS countries - By service, age and	



	sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	0
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	0
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	0
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	8,005
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	12,830
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	3,142
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	
	Required only for DREAMS countries - By service, age and	



	sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	34
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	60
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	4,398
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	7,889
	Required only for DREAMS countries - By service, age and	



	sex: Social Protection Female 25+	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	26,767
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	16,229
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening	0



	Female 25+	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	7,965
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and	



	sex: Other Services Female 25+	
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	
	Age/Sex: <1	36,010
	Age/Sex: 1-9	302,307
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	
	Required only for DREAMS countries - By service, age and	



	sex: Other Services Male 1-9	
	Program Completion: Active	651,231
	Program Completion: Graduation	80,547
	Program Completion: Transferred	30
	Program Completion: Exited without graduation	79,831
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	37 %



	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	19,715
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	52,762
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and	



	relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during	



	the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	50
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10,556
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30
	Aggregated Age/Sex: Female 15+	9,079



	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of	



	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented	



	HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2,159
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	23,518
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1,438



	treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	16,665
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	50 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	106,882
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	213,485
	By Age/Sex (Denominator): <15, Female	9,731
	By Age/Sex (Denominator): <15, Male	13,140
	By Age/Sex (Denominator): 15+, Female	80,782
	By Age/Sex (Denominator): 15+, Male	109,662
	By Therapy type (Denominator):	213,231



	6-12 Month IPT	
	By Therapy type (Denominator): Alternative Regimen	0
	By Therapy type (Denominator): Continuous IPT	3
	By Age/Sex (Numerator): <15, Female	4,596
	By Age/Sex (Numerator): <15, Male	6,313
	By Age/Sex (Numerator): 15+, Female	40,832
	By Age/Sex (Numerator): 15+, Male	55,116
	By Therapy type (Numerator): 6-12 Month IPT	106,867
	By Therapy type (Numerator): Alternative Regimen	0
	By Therapy type (Numerator): Continuous IPT	4
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	2 %
	Number of ART patients who were started on TB treatment during the reporting period.	29,392
	Number of ART patients who were screened for TB at least once during the reporting period	1,184,139
	Numerator: By Aggregated Age/Sex: <15, Female	1,066
	Numerator: By Aggregated Age/Sex: <15, Male	1,594
	Numerator: By Aggregated Age/Sex: 15+, Female	11,048



	Numerator: By Aggregated Age/Sex: 15+, Male	15,541
	Denominator: By Aggregated Age/Sex: <15, Female	44,509
	Denominator: By Aggregated Age/Sex: <15, Male	63,248
	Denominator: By Aggregated Age/Sex: 15+, Female	400,238
	Denominator: By Aggregated Age/Sex: 15+, Male	567,697
	Denominator: By Screen Result: Negative	1,135,355
	Denominator: By Screen Result: Positive	39,272
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	29,439
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	347
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	16,360
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	14,829
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	56,774
	Number of HIV- positive pregnant	



	women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	839
	Number of infants with a positive virological test result within 12 months of birth	
	Unknown, <= 2 months	15
	Unknown, 2 - 12 months	5
	Number of infants with a negative virological test result within 2 months of birth	41,799
	Number of infants with a positive virological test result between 2 and 12 months of birth	637
	Number of infants with a negative virological test result between 2 and 12 months of birth	13,479
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,246,143
	Age/Sex: 15-19 Male	11,883
	Age/Sex: 15-19 Female	6,180



	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	28,060
	Aggregated Age/Sex: 15+ Male	296,511
	Aggregated Age/Sex: <15 Female	36,972
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	636,037
	Sum of Aggregated Age/Sex <15	65,032
	Sum of Aggregated Age/Sex 15+	932,548
	Sum of Aggregated Age/Sex disaggregates	997,580
	Age/Sex: <1	283
	Age/Sex: <1-9	7,977
	Age/Sex: 10-14 Male	3,686
	Age/Sex: 10-14 Female	2,993
	Aggregated Age/Sex: 1-14 Male	
	Age/Sex: 20-24 Male	19,551
	Age/Sex: 25-49 Male	42,762
	Age/Sex: 50+ Male	17,159
	Age/Sex: 20-24 Female	16,453
	Age/Sex: 25-49 Female	101,408
	Age/Sex: 50+ Female	17,619
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	359,541
	By Age/Sex: <1	416
	By Age/Sex: 1-9	1,809
	By Age/Sex: 10-14 Male	453
	By Age/Sex: 15-19 Male	594
	By Age/Sex: 20-24 Male	525
	By Age/Sex: 25-49 Male	8,155



	By Age/Sex: 50+ Male	1,895
	By Age/Sex: 10-14 Female	483
	By Age/Sex: 15-19 Female	1,489
	By Age/Sex: 20-24 Female	3,639
	By Age/Sex: 25-49 Female	18,370
	By Age/Sex: 50+ Female	2,374
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	7,684
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	90,001
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	10,538
	Aggregated Grouping by Age/Sex: 15+ Female	194,567
	Pregnancy status	29,693
	Breastfeeding status	5,601
	FSW	0
	MSM	0
	People in prisons and other enclosed settings	0
	TG	0
	Aggregated Grouping by Age/Sex: 1-14 Female	
	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	TX_PVLS_DSD Percentage of	90 %



	ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	913,654
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,018,414
	Numerator: Indication: Routine	820,995
	Numerator: Indication: Targeted	91,246
	Numerator: Preg/BF by Indication: Pregnant Routine	21,385
	Numerator: Preg/BF by Indication: Breastfeeding Routine	894
	Numerator: Preg/BF by Indication: Pregnant Targeted	2,643
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	438
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	



	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	



	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	2,421
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	28,253
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	3,402
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	57,301
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	21,789
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	254,265
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	29,713
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	512,141
	Denominator: Indication: Routine	914,505
	Denominator: Indication: Targeted	101,460
	Denominator: Preg/BF by Indication: Pregnant Routine	23,845
	Denominator: Preg/BF by Indication: Breastfeeding Routine	1,015
	Denominator: Preg/BF by Indication: Pregnant Targeted	2,988
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	464
	Denominator: Age/Sex by Indication: <1 Routine	



	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	



	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	2,602
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	31,555
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	3,631
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	64,005
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	25,840
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	282,172
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	35,715
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	566,742
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	



Numerator Aggregated Age/Sex: 15+ Female	
Denominator Aggregated Age/Sex: <15 Male	
Denominator Aggregated Age/Sex: 15+ Male	
Denominator Aggregated Age/Sex: <15 Female	
Denominator Aggregated Age/Sex: 15+ Female	
<15, Routine, Unknown Sex	11
<15, Targeted, Unknown Sex	1
<15, Undocumented Test Indication, Female	20
<15, Undocumented Test Indication, Male	20
<15, Undocumented Test Indication, Unknown Sex	0
15+, Routine, Unknown Sex	140
15+, Targeted, Unknown Sex	15
15+, Undocumented Test Indication, Female	766
15+, Undocumented Test Indication, Male	764
15+, Undocumented Test Indication, Unknown Sex	0
Unknown Age, Routine, Female	73
Unknown Age, Routine, Male	43
Unknown Age, Routine, Unknown Sex	0
Unknown Age, Targeted, Female	0
Unknown Age, Targeted, Male	0
Unknown Age, Targeted, Unknown Sex	0



	Unknown Age, Undocumented Test Indication, Female	1
	Unknown Age, Undocumented Test Indication, Male	0
	Unknown Age, Undocumented Test Indication, Unknown Sex	0
	Breastfeeding, Undocumented Test Indication	1
	Pregnant, Undocumented Test Indication	30
	Undocumented Test Indication	1,579
	<15, Routine, Unknown Sex	32
	<15, Targeted, Unknown Sex	3
	<15, Undocumented Test Indication, Female	18
	<15, Undocumented Test Indication, Male	18
	<15, Undocumented Test Indication, Unknown Sex	0
	15+, Routine, Unknown Sex	466
	15+, Targeted, Unknown Sex	49
	15+, Undocumented Test Indication, Female	692
	15+, Undocumented Test Indication, Male	687
	15+, Undocumented Test Indication, Unknown Sex	0
	Unknown Age, Routine, Female	1
	Unknown Age, Routine, Male	1
	Unknown Age, Routine, Unknown Sex	0
	Unknown Age, Targeted, Female	12
	Unknown Age, Targeted, Male	7



	Unknown Age, Targeted, Unknown Sex	0
	Unknown Age, Undocumented Test Indication, Female	0
	Unknown Age, Undocumented Test Indication, Male	0
	Unknown Age, Undocumented Test Indication, Unknown Sex	0
	Breastfeeding, Undocumented Test Indication	1
	Pregnant, Undocumented Test Indication	31
	Undocumented Test Indication	1,413
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	85 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	227,027
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	267,993
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	



	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	



	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female	



	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: )	



	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	6,331
	Numerator by Status: Breastfeeding	5,489
	Denominator by Status: Pregnant	8,214
	Denominator by Status: Breastfeeding	5,753
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,382
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	56,969



	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,017
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	151,296
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,816
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	67,687
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,668
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of	178,777



	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	18,734
	By Graduates: Doctors	169
	By Graduates: Nurses	3,629
	By Graduates: Midwives	573
	By Graduates: Social service workers	0
	By Graduates: Laboratory professionals	329
	By Graduates: Other	14,034
	Sum of Graduates disaggreagtes	18,734



## Partners and Implementing Mechanisms

### Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7241	PharmAccess	NGO	U.S. Department of Defense	GHP-State	0
9618	Touch Foundation	NGO	U.S. Agency for International Development	GHP-State	0
10970	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	300,000
11528	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	113,000
12854	Vodafone Foundation	NGO	U.S. Agency for International Development	GHP-State	0
14691	National Council for People Living with HIV/AIDS Tanzania	NGO	U.S. Agency for International Development	GHP-State	607,772
14692	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	2,050,000
14693	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	5,050,000
14698	United Nations Children's Fund	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	17,747
16569	University of North	University	U.S. Agency for	GHP-State	308,056



	Carolina		International Development		
16784	JHPIEGO	University	U.S. Agency for International Development	GHP-State	29,413,895
16787	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	1,779,776
16874	Tanzania Health Promotion Support (THPS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,140,378
16885	Muhimbili University College of Health Sciences	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
16886	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	140,000
16891	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000



16892	American Society of Clinical Pathology	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	375,000
16899	Management development for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	971,300
17082	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	800,000
17102	Muhimbili University College of Health Sciences	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	300,000
17103	Baylor College of Medicine International Pediatric AIDS Initiative/Tanzania	University	U.S. Agency for International Development	GHP-State	1,750,370
17292	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000



17293	Management development for Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	15,098,193
17296	Cardno Emerging Markets	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,420,000
17300	National Institute for Medical Research	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	800,000
17304	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	500,000
17305	American International Health Alliance	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	2,350,000
17316	United Nations	Multi-lateral	U.S. Department	GHP-State	510,000



	Children's Fund	Agency	of Health and Human Services/Centers for Disease Control and Prevention		
17358	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	11,324,762
17409	JHPIEGO	University	U.S. Agency for International Development	GHP-State	0
17416	T-MARC Tanzania	NGO	U.S. Agency for International Development	GHP-State	0
17420	KNCV Tuberculosis Foundation	NGO	U.S. Agency for International Development	GHP-State	1,351,458
17985	Africa Society for Bloods Transfusions	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	320,000
17986	Ariel Glaser Pediatric AIDS Healthcare Initiative	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	33,161,263
17987	Management Sciences for Health	NGO	U.S. Department of Health and Human Services/Centers	GHP-State	1,890,000



			for Disease Control and Prevention		
17988	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,250,000
17990	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,550,000
17991	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	10,137,499
17992	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
18056	FHI 360	NGO	U.S. Agency for International Development	GHP-State	1,250,000
18058	Abt Associates	Private Contractor	U.S. Agency for International	GHP-State	1,300,000



			Development		
18060	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Agency for International Development	GHP-State	8,572,436
18061	Futures Group	Private Contractor	U.S. Agency for International Development	GHP-State	400,000
18072	New Partner	TBD	U.S. Agency for International Development	GHP-State	3,700,000
18130	Research Triangle International	Private Contractor	U.S. Department of Defense	GHP-State	49,536
18131	IntraHealth International, Inc	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,113,995
18170	Ministry of Health and Social Welfare, Tanzania	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,640,265
18171	TBD	TBD	Redacted	Redacted	Redacted
18198	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	119,213,235
18200	Global Health Supply Chain Program	Private Contractor	U.S. Agency for International Development	GHP-State	2,390,000
18237	Deloitte Consulting	Private Contractor	U.S. Agency for International	GHP-State	6,982,486



	Limited		Development		
18243	African Field Epidemiology Network	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
18488	TBD	TBD	Redacted	Redacted	Redacted
18489	TBD	TBD	Redacted	Redacted	Redacted
18621	New Partner	TBD	U.S. Agency for International Development	GHP-State	400,000
18622	Right to Care	NGO	U.S. Agency for International Development	GHP-State	400,000
18627	TBD	TBD	Redacted	Redacted	Redacted
18628	TBD	TBD	Redacted	Redacted	Redacted
18629	Health Research Inc./New York State Department of Health	Other USG Agency	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	400,000



## Implementing Mechanism(s)

### Implementing Mechanism Details

<b>Mechanism ID: 7241</b>	<b>Mechanism Name: PAI-DOD</b>
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: PharmAccess	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	7241		
<b>Mechanism Name:</b>	PAI-DOD		
<b>Prime Partner Name:</b>	PharmAccess		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 9618</b>	<b>Mechanism Name: Touch Foundation- PPP</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Touch Foundation	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 750,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 750,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	9618		
<b>Mechanism Name:</b>	Touch Foundation- PPP		
<b>Prime Partner Name:</b>	Touch Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

**Implementing Mechanism Indicator Information**

<b>Indicator Number</b>	<b>Label</b>	<b>2018</b>
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the	698



	reporting period, by select cadre	
HRH_PRE	By Graduates: Doctors	165
HRH_PRE	By Graduates: Nurses	100
HRH_PRE	By Graduates: Midwives	0
HRH_PRE	By Graduates: Social service workers	0
HRH_PRE	By Graduates: Laboratory professionals	324
HRH_PRE	By Graduates: Other	109
HRH_PRE	Sum of Graduates disaggreagtes	698

### Implementing Mechanism Details

<b>Mechanism ID: 10970</b>	<b>Mechanism Name: Ambassador's HIV/AIDS Relief Fund</b>
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	300,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 10970</b>
----------------------------



<b>Mechanism Name:</b> Ambassador's HIV/AIDS Relief Fund			
<b>Prime Partner Name:</b> U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	150,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 11528</b>		<b>Mechanism Name: U.S. Peace Corps</b>	
Funding Agency: PC		Procurement Type: USG Core	
Prime Partner Name: U.S. Peace Corps			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	

<b>Total All Funding Sources: 113,000</b>		<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 113,000</b>			
<b>Total All Funding Sources and Applied Pipeline Amount: 226,000</b>			
Funding Source	Funding Amount		
GHP-State	113,000		

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 11528			
<b>Mechanism Name:</b> U.S. Peace Corps			
<b>Prime Partner Name:</b> U.S. Peace Corps			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	113,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 12854		<b>Mechanism Name:</b> Vodafone Foundation PPP	
Funding Agency: USAID		Procurement Type: Cooperative Agreement	
Prime Partner Name: Vodafone Foundation			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: No		Managing Agency:	
<b>Total All Funding Sources: 0</b>		<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 0</b>			
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>			
<b>Funding Source</b>		<b>Funding Amount</b>	
GHP-State		0	

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	12854		
<b>Mechanism Name:</b>	Vodafone Foundation PPP		
<b>Prime Partner Name:</b>	Vodafone Foundation		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14691</b>	<b>Mechanism Name: Citizens engaging in government oversight (CEGO) (CSO Grants: Advocacy)</b>
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: National Council for People Living with HIV/AIDS Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 607,772</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 748,801</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,356,573</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	607,772

### Cross-Cutting Budget Attribution(s)

Key Populations: FSW	100,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: GBV	239,493
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	300,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Economic Strengthening	200,000
Water	250,000
Food and Nutrition: Commodities	100,000

### Budget Code Information

<b>Mechanism ID:</b>	14691
<b>Mechanism Name:</b>	Citizens engaging in government oversight (CEGO) (CSO Grants: Advocacy)
<b>Prime Partner Name:</b>	National Council for People Living with HIV/AIDS Tanzania



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	607,772	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14692</b>	<b>Mechanism Name: Community Health and Social Systems Strengthening Program (CHSSP)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,050,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 1,500,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,550,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,050,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	2,050,000
----------------------------	-----------

### Budget Code Information

<b>Mechanism ID: 14692</b>
----------------------------



<b>Mechanism Name:</b>	<b>Community Health and Social Systems Strengthening Program (CHSSP)</b>		
<b>Prime Partner Name:</b>	<b>John Snow Inc (JSI)</b>		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	1,850,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	13,773
HRH_PRE	By Graduates: Other	13,773
HRH_PRE	Sum of Graduates disaggreagtes	13,773

### Implementing Mechanism Details

<b>Mechanism ID: 14693</b>	<b>Mechanism Name: Public Sector System Strengthening (PS3)</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 5,050,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 1,800,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,850,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>



GHP-State	5,050,000
-----------	-----------

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	122,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Economic Strengthening	122,000
Education	122,000
Water	122,000
Human Resources for Health	1,220,000

**Budget Code Information**

<b>Mechanism ID:</b>	14693		
<b>Mechanism Name:</b>	Public Sector System Strengthening (PS3)		
<b>Prime Partner Name:</b>	Abt Associates		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	2,750,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	550,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	HTXS	1,350,000	0
-----------	------	-----------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 14698</b>	<b>Mechanism Name: National Capacity Building</b>
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 17,747</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 182,253</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 200,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	17,747

### Cross-Cutting Budget Attribution(s)

Gender: GBV	8,873
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	8,873
Focus Area:	Promoting gender-related policies and laws that increase legal protection



### Budget Code Information

<b>Mechanism ID:</b> 14698			
<b>Mechanism Name:</b> National Capacity Building			
<b>Prime Partner Name:</b> United Nations Children's Fund			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	17,747	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 16569	<b>Mechanism Name:</b> MEASURE Associate Award
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 308,056	<b>Total Mechanism Pipeline:</b> N/A
<b>Applied Pipeline Amount:</b> 1,316,944	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 1,625,000	
Funding Source	Funding Amount
GHP-State	308,056

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	308,056
----------------------------	---------



### Budget Code Information

<b>Mechanism ID:</b>	16569		
<b>Mechanism Name:</b>	MEASURE Associate Award		
<b>Prime Partner Name:</b>	University of North Carolina		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	166,528	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	141,528	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16784</b>	<b>Mechanism Name: Sauti za Watanzania</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 29,413,895</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 2,300,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 31,713,895</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	29,413,895

### Cross-Cutting Budget Attribution(s)



Key Populations: FSW	5,400,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	1,300,705
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	540,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building



Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Key Populations: MSM and TG	5,400,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Food and Nutrition: Commodities	270,000
Condom programming	360,000
Economic Strengthening	900,000
Food and Nutrition: Policy, Tools, and Service Delivery	270,000
Education	180,000

### Budget Code Information

<b>Mechanism ID:</b>	16784
<b>Mechanism Name:</b>	Sauti za Watanzania
<b>Prime Partner Name:</b>	JHPIEGO



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	1,077,365	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	2,016,274	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	11,479,021	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	13,741,235	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,100,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	4,192
PrEP_NEW_DSD	Female 15-19	253
PrEP_NEW_DSD	Female 20-24	920
PrEP_NEW_DSD	Female 25-49	3,019
PrEP_NEW_DSD	Female 50+	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	112,799
PP_PREV_DSD	Age/sex: 15-19 Female	54,050
PP_PREV_DSD	Age/sex: 20-24 Female	58,635
PP_PREV_DSD	Age/sex: 25-49 Female	114
PP_PREV_DSD	Sum of Age/Sex disaggregates	112,799



KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	56,706
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	6,565
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	50,141
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,141,053
HTC_TST_DSD	By Test Result: Positive	36,562
HTC_TST_DSD	Sum of Test Result disaggregates	36,562
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	0



HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Negative	0



HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) by Aggregated Age: Homebased testing: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	4,370
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	117
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	3,570
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	77
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	8,121
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	396
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	9,159
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	319



	15-19, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	16,249
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	785
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	18,326
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	650
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	45,790
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	2,212
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	51,641
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	1,820
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	3,694
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	178
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	4,136
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	150
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	47,414
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	750
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile	38,842



	Testing: <15, Male, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	483
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	170,921
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	7,279
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	192,732
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	6,039
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	0
HTC_TST_DSD	By Key Population: FSW, Negative	0
HTC_TST_DSD	By Key Population: FSW, Positive	0
HTC_TST_DSD	By Key Population: MSM, Negative	0
HTC_TST_DSD	By Key Population: MSM, Positive	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	0
HTC_TST_DSD	By Key Population: PWID, Positive	0
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	6,549



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	166
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	5,364
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	124
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	5,432
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	265
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	6,131
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	221
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	10,864
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	527
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	12,251
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	434
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	30,620
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	1,480
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	34,515
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	1,231
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	2,468
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	126



HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2,741
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	106
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	71,070
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	1,086
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	58,314
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	766
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	114,228
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	4,857
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	128,790
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	4,108
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	0



HTC_TST_DSD	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	33,740
OVC_SERV_DSD	Age/Sex: 10-14 Female	0
OVC_SERV_DSD	Age/Sex: 15-17 Female	23,062
OVC_SERV_DSD	By: Age/sex: 18-24 Female	10,678
OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	23,062
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	688
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	3,142
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	34
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	60
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	4,398
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	7,889
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	23,068
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	10,678
OVC_SERV_DSD	Program Completion: Active	27,314
OVC_SERV_DSD	Program Completion: Graduation	3,386
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	3,040

### Implementing Mechanism Details

<b>Mechanism ID: 16787</b>	<b>Mechanism Name: Strengthening High Impact Interventions for an AIDS-Free Generation</b>
----------------------------	--



	<b>(AIDSFree) Project</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow Inc (JSI)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,779,776</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 3,725,951</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,505,727</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,779,776

### Cross-Cutting Budget Attribution(s)

Gender: GBV	256,200
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Condom programming	42,000

### Budget Code Information

<b>Mechanism ID:</b>	<b>16787</b>
<b>Mechanism Name:</b>	<b>Strengthening High Impact Interventions for an AIDS-Free Generation</b>
<b>Prime Partner Name:</b>	<b>(AIDSFree) Project</b>
	<b>John Snow Inc (JSI)</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	24,352	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	3,444	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	1,032,085	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	420,413	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	18,900	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	279,980	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	602	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	770
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,522
PMTCT_ART_DSD	New on ART	464
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	306



PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	15,522
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,561
PMTCT_STAT_DSD	By Age (Denominator): 20-24	5,807
PMTCT_STAT_DSD	By Age (Denominator): 25-49	8,048
PMTCT_STAT_DSD	By Number of known positives: 15-19	26
PMTCT_STAT_DSD	By Number of known positives: 20-24	87
PMTCT_STAT_DSD	By Number of known positives: 25-49	172
PMTCT_STAT_DSD	By Number of new positives: 15-19	47
PMTCT_STAT_DSD	By Number of new positives: 20-24	185
PMTCT_STAT_DSD	By Number of new positives: 25-49	304
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,224
PMTCT_STAT_DSD	By Number of new negative: 20-24	5,229
PMTCT_STAT_DSD	By Number of new negative: 25-49	7,248
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,298
PMTCT_STAT_DSD	By Age (Numerator): 20-24	5,501
PMTCT_STAT_DSD	By Age (Numerator): 25-49	7,723
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	146,561
VMMC_CIRC_DSD	By Age: 0-60 days	9,294
VMMC_CIRC_DSD	By Age: 10-14	70,559
VMMC_CIRC_DSD	By Age: 15-19	34,217
VMMC_CIRC_DSD	By Age: 20-24	12,927
VMMC_CIRC_DSD	By Age: 25-29	21,358
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	117,703
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	139,061
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	138,567
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	7,574
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	206,497



HTC_TST_DSD	By Test Result: Positive	7,353
HTC_TST_DSD	Sum of Test Result disaggregates	7,353
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	2,447
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,625
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	179
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	148
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	464
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	370
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	1,033
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	71
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	927
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	56



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	137
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	71
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	77
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	1,909
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	1,254
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	1,005
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	796
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,817
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	90
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	2,217
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	6,434



	25-49, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	201
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	5,642
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	169
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	806
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	402
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3,515
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	2,337
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,519
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,062
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	7,085



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	419
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	5,581
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	335
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	16,148
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	973
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	14,748
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	859
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,042
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	120
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,039
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	684
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14,	4,701



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	42,171
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	742
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	13,527
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	357
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	9,392
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	190
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <15, Negative	752
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	13
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	1,127
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,653
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,100
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	197
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	29



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	497
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	112
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	394
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	1,102
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	259
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	983
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	221
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	268
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	2,877
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	1,896
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	45



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	656
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	530
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	1,852
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	89
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	1,464
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	4,269
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	192
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	3,711
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	171
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	527
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	260
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9,	102



	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,123
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	5,464
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	194
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	7,009
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	297
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	766
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	14
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	585
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	3
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	164
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,198
TX_CURR_DSD	Age/Sex: 15-19 Male	150
TX_CURR_DSD	Age/Sex: 15-19 Female	305
TX_CURR_DSD	Sum of age/sex disaggregates	455
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	190
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	3,447
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	175
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	5,404
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	365
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	8,851
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	9,216
TX_CURR_DSD	Age/Sex: <1	2
TX_CURR_DSD	Age/Sex: <1-9	182
TX_CURR_DSD	Age/Sex: 10-14 Male	42
TX_CURR_DSD	Age/Sex: 10-14 Female	47



TX_CURR_DSD	Age/Sex: 20-24 Male	136
TX_CURR_DSD	Age/Sex: 25-49 Male	1,429
TX_CURR_DSD	Age/Sex: 50+ Male	207
TX_CURR_DSD	Age/Sex: 20-24 Female	734
TX_CURR_DSD	Age/Sex: 25-49 Female	2,415
TX_CURR_DSD	Age/Sex: 50+ Female	332
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,162
TX_NEW_DSD	By Age/Sex: <1	1
TX_NEW_DSD	By Age/Sex: 1-9	41
TX_NEW_DSD	By Age/Sex: 10-14 Male	28
TX_NEW_DSD	By Age/Sex: 15-19 Male	37
TX_NEW_DSD	By Age/Sex: 20-24 Male	6
TX_NEW_DSD	By Age/Sex: 25-49 Male	170
TX_NEW_DSD	By Age/Sex: 50+ Male	20
TX_NEW_DSD	By Age/Sex: 10-14 Female	15
TX_NEW_DSD	By Age/Sex: 15-19 Female	88
TX_NEW_DSD	By Age/Sex: 20-24 Female	149
TX_NEW_DSD	By Age/Sex: 25-49 Female	639
TX_NEW_DSD	By Age/Sex: 50+ Female	61
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,213
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	47
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,331
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	58
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,471
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,907
TX_NEW_DSD	Pregnancy status	222
TX_NEW_DSD	Breastfeeding status	24
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,264



TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	11,408
TX_PVLS_DSD	Numerator: Indication: Routine	9,234
TX_PVLS_DSD	Numerator: Indication: Targeted	1,030
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	195
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	16
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	50
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	1
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	21
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	358
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	18
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	614
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	201
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,249
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	193
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	5,593
TX_PVLS_DSD	Denominator: Indication: Routine	10,263
TX_PVLS_DSD	Denominator: Indication: Targeted	1,141
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	204
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	16
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	53
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding	1



	Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	21
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	399
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	19
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	690
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	217
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,614
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	212
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,217
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,983
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,856
TX_RET_DSD	Numerator by Status: Pregnant	72
TX_RET_DSD	Numerator by Status: Breastfeeding	26
TX_RET_DSD	Denominator by Status: Pregnant	82
TX_RET_DSD	Denominator by Status: Breastfeeding	29
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,044
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,546
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number	947



	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,433
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,228
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,816
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,114
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,697
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,260
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,519



TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	98
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	152
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	914
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,355
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	2,519
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	52
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	73
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	458
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	679
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	1,260
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	363
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	14,443
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	9
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	17
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	131
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	206
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	577
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	864
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	5,203
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	7,798
TX_TB_DSD	Denominator: By Screen Result: Negative	14,081
TX_TB_DSD	Denominator: By Screen Result: Positive	363

### Implementing Mechanism Details

<b>Mechanism ID: 16874</b>	<b>Mechanism Name: Local FOA Follow-on - (GH001068)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: Tanzania Health Promotion Support (THPS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 4,140,378</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 4,140,378</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	4,140,378

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 16874</b>			
<b>Mechanism Name: Local FOA Follow-on - (GH001068)</b>			
<b>Prime Partner Name: Tanzania Health Promotion Support (THPS)</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	185,030	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	26,954	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	250,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	471,342	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	68,432	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	289,208	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	448,770	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	2,227,857	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	172,785	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,030
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	61,316
PMTCT_ART_DSD	New on ART	1,348
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	682
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	61,316
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	65,173



PMTCT_STAT_DSD	By Number of known positives: Unknown Age	1,094
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	1,033
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	59,188
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	61,314
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	1,061
KP_MAT_DSD	Sex: Male	789
KP_MAT_DSD	Sex: Female	272
KP_MAT_DSD	Sum of Sex disaggregates	1,061
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	331
PP_PREV_DSD	Age/sex: 20-24 Male	211
PP_PREV_DSD	Age/sex: 20-24 Female	120
PP_PREV_DSD	Sum of Age/Sex disaggregates	331
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,653
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	325
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,001
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet	1,221



	the minimum standards required)	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	106
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	459,728
HTC_TST_DSD	By Test Result: Positive	18,230
HTC_TST_DSD	Sum of Test Result disaggregates	18,230
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	7,192
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	47
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	7,191
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	47
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	28,434
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	1,536
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	13,040
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	721
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient:	0



	Unknown Age, Male, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	37,125
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	337
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	37,128
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	339
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	179,034
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	9,381
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	71,555
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	4,400
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	242
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	13
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	242
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	13
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+,	352



	Female, Negative	
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	215
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	775
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	148
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	59,188
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	1,033
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
GEND_GBV_DSD	Number of people receiving post-GBV care	5,057
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,367
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,690
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,690
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,025
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	45
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,649
PMTCT_EID_DSD	Number of infants with a positive virological test result	8



	between 2 and 12 months of birth	
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	323
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	64,611
TX_CURR_DSD	Age/Sex: 15-19 Male	4
TX_CURR_DSD	Age/Sex: 15-19 Female	5
TX_CURR_DSD	Sum of age/sex disaggregates	9
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,004
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	16,830
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,137
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	43,368
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	4,141
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	60,198
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	64,339
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	10
TX_CURR_DSD	Age/Sex: 10-14 Male	4
TX_CURR_DSD	Age/Sex: 10-14 Female	9
TX_CURR_DSD	Age/Sex: 20-24 Male	2
TX_CURR_DSD	Age/Sex: 25-49 Male	55
TX_CURR_DSD	Age/Sex: 50+ Male	31
TX_CURR_DSD	Age/Sex: 20-24 Female	8
TX_CURR_DSD	Age/Sex: 25-49 Female	105
TX_CURR_DSD	Age/Sex: 50+ Female	34
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	18,949
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	0
TX_NEW_DSD	By Age/Sex: 10-14 Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	0
TX_NEW_DSD	By Age/Sex: 20-24 Male	0



TX_NEW_DSD	By Age/Sex: 25-49 Male	1
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 10-14 Female	0
TX_NEW_DSD	By Age/Sex: 15-19 Female	0
TX_NEW_DSD	By Age/Sex: 20-24 Female	1
TX_NEW_DSD	By Age/Sex: 25-49 Female	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	2
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	491
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	5,192
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	601
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	12,660
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	18,944
TX_NEW_DSD	Pregnancy status	1,344
TX_NEW_DSD	Breastfeeding status	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	43,478
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	48,385
TX_PVLS_DSD	Numerator: Indication: Routine	39,129
TX_PVLS_DSD	Numerator: Indication: Targeted	4,349
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	137
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male	1,126



	Targeted	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	144
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,937
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,224
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	10,138
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,299
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	26,470
TX_PVLS_DSD	Denominator: Indication: Routine	43,544
TX_PVLS_DSD	Denominator: Indication: Targeted	4,835
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	146
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,254
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	153
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,236
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,349
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	11,193
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,446
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	29,080
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0



TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	16,105
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	18,941
TX_RET_DSD	Numerator by Status: Pregnant	1,151
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	1,341
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	413
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,412
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	517
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,756
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	490
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	5,313



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	597
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12,536
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	5,607
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	10,937
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	646
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	437
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	5,908
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	3,946
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	10,937
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	327
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	216
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,035
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,029



TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	5,607
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	1,535
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	61,405
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	82
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	55
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	864
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	534
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,685
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,462
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	33,179
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	22,079
TX_TB_DSD	Denominator: By Screen Result: Negative	59,881
TX_TB_DSD	Denominator: By Screen Result: Positive	1,524

### Implementing Mechanism Details

<b>Mechanism ID: 16885</b>	<b>Mechanism Name: MUHAS-TAPP - (GH000837)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Muhimbili University College of Health Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 0</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

Approved



(No data provided.)

**Budget Code Information**

<b>Mechanism ID: 16885</b>			
<b>Mechanism Name: MUHAS-TAPP - (GH000837)</b>			
<b>Prime Partner Name: Muhimbili University College of Health Sciences</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	0	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 16886</b>	<b>Mechanism Name: WHO Follow-on - (GH001180)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 140,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 140,000</b>	
Funding Source	Funding Amount
GHP-State	140,000



### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	16886		
<b>Mechanism Name:</b>	WHO Follow-on - (GH001180)		
<b>Prime Partner Name:</b>	World Health Organization		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	140,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 16891</b>	<b>Mechanism Name: CLSI Lab - (GH001114)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 250,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 250,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	250,000



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 16891			
<b>Mechanism Name:</b> CLSI Lab - (GH001114)			
<b>Prime Partner Name:</b> Clinical and Laboratory Standards Institute			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	250,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 16892	<b>Mechanism Name:</b> ASCP Lab - (GH001096)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Society of Clinical Pathology	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources:</b> 375,000	<b>Total Mechanism Pipeline:</b> N/A
<b>Applied Pipeline Amount:</b> 0	
<b>Total All Funding Sources and Applied Pipeline Amount:</b> 375,000	
Funding Source	Funding Amount



GHP-State	375,000
-----------	---------

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 16892			
<b>Mechanism Name:</b> ASCP Lab - (GH001096)			
<b>Prime Partner Name:</b> American Society of Clinical Pathology			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	75,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 16899	<b>Mechanism Name:</b> HIS - UCC follow on - (GH001361)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Management development for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

Approved



G2G: No	Managing Agency:
<b>Total All Funding Sources: 971,300</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 971,300</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	971,300

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID: 16899</b>			
<b>Mechanism Name: HIS - UCC follow on - (GH001361)</b>			
<b>Prime Partner Name: Management development for Health</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	349,300	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	422,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details



<b>Mechanism ID: 17082</b>	<b>Mechanism Name: ASSIST</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 800,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 1,500,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,300,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	800,000

**Cross-Cutting Budget Attribution(s)**

Gender: Gender Equality	200,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Capacity building
Human Resources for Health	300,000

**Budget Code Information**

<b>Mechanism ID: 17082</b>			
<b>Mechanism Name: ASSIST</b>			
<b>Prime Partner Name: University Research Corporation, LLC</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	700,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	100,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17102</b>	<b>Mechanism Name: MUHAS SPH Follow On - (GH001075)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Muhimbili University College of Health Sciences	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

<b>Total All Funding Sources: 300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 300,000</b>	
Funding Source	Funding Amount
GHP-State	300,000

### Cross-Cutting Budget Attribution(s)



Human Resources for Health	150,000
----------------------------	---------

### Budget Code Information

<b>Mechanism ID:</b> 17102			
<b>Mechanism Name:</b> MUHAS SPH Follow On - (GH001075)			
<b>Prime Partner Name:</b> Muhimbili University College of Health Sciences			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	300,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	800
KP_MAT_DSD	Sex: Male	760
KP_MAT_DSD	Sex: Female	40
KP_MAT_DSD	Sum of Sex disaggregates	800
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	111
HRH_PRE	By Graduates: Other	111
HRH_PRE	Sum of Graduates disaggreagtes	111

### Implementing Mechanism Details

<b>Mechanism ID:</b> 17103	<b>Mechanism Name:</b> BIPAI-PPP (linked to BIPAI-PPP 10070)
----------------------------	--



Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Baylor College of Medicine International Pediatric AIDS Initiative/Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,750,370</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 196,874</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,947,244</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,750,370

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	12,267
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Food and Nutrition: Commodities	29,837
Human Resources for Health	250,000
Economic Strengthening	29,494
Education	99,676
Food and Nutrition: Policy, Tools, and Service Delivery	148,578

**Budget Code Information**

<b>Mechanism ID:</b>	17103
<b>Mechanism Name:</b>	BIPAI-PPP (linked to BIPAI-PPP 10070)
<b>Prime Partner Name:</b>	Baylor College of Medicine International Pediatric AIDS Initiative/Tanzania



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	6,030	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	4,718	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	35,764	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,703,858	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,307
HTC_TST_DSD	By Test Result: Positive	359
HTC_TST_DSD	Sum of Test Result disaggregates	359
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	150
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19,	130



	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	130
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	123
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	180
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	180
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown	0



	Age, Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	383
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,030
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	70
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	561
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	69
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	507
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	37
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	193
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	47
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	63
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other	1



	PITC: Unknown Age, Male, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	2,486
TX_CURR_DSD	Age/Sex: 15-19 Male	47
TX_CURR_DSD	Age/Sex: 15-19 Female	53
TX_CURR_DSD	Sum of age/sex disaggregates	100
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	421
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	124
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	449
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	95
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	870
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	219
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,089
TX_CURR_DSD	Age/Sex: <1	23
TX_CURR_DSD	Age/Sex: <1-9	651
TX_CURR_DSD	Age/Sex: 10-14 Male	289
TX_CURR_DSD	Age/Sex: 10-14 Female	302
TX_CURR_DSD	Age/Sex: 20-24 Male	2
TX_CURR_DSD	Age/Sex: 25-49 Male	1
TX_CURR_DSD	Age/Sex: 50+ Male	0
TX_CURR_DSD	Age/Sex: 20-24 Female	17
TX_CURR_DSD	Age/Sex: 25-49 Female	11
TX_CURR_DSD	Age/Sex: 50+ Female	0
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	448
TX_NEW_DSD	By Age/Sex: <1	78
TX_NEW_DSD	By Age/Sex: 1-9	101
TX_NEW_DSD	By Age/Sex: 10-14 Male	16
TX_NEW_DSD	By Age/Sex: 15-19 Male	23
TX_NEW_DSD	By Age/Sex: 20-24 Male	0



TX_NEW_DSD	By Age/Sex: 25-49 Male	0
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 10-14 Female	27
TX_NEW_DSD	By Age/Sex: 15-19 Female	19
TX_NEW_DSD	By Age/Sex: 20-24 Female	8
TX_NEW_DSD	By Age/Sex: 25-49 Female	23
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	116
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	43
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	12
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	72
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	26
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	153
TX_NEW_DSD	Pregnancy status	0
TX_NEW_DSD	Breastfeeding status	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,678
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,865
TX_PVLS_DSD	Numerator: Indication: Routine	1,510
TX_PVLS_DSD	Numerator: Indication: Targeted	168
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	58
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male	21



	Targeted	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	62
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	27
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	523
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	185
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	563
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	238
TX_PVLS_DSD	Denominator: Indication: Routine	1,678
TX_PVLS_DSD	Denominator: Indication: Targeted	187
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	64
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	23
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	70
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	29
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	581
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	207
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15	625



	Female Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	264
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0



TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	381
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	448
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	138
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	35



TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	155
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	53
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	162
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	182
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	63
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	159
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting	317



	period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	13
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	19
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	114
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	171
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	317
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	6
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	10
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	57
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	86
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	159
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	59
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	2,361
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	4
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	21
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	32
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	94
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	142
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	849
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	1,275
TX_TB_DSD	Denominator: By Screen Result: Negative	2,302
TX_TB_DSD	Denominator: By Screen Result: Positive	59

### Implementing Mechanism Details

<b>Mechanism ID: 17292</b>	<b>Mechanism Name: APHL Lab Follow on - (GH001097)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Approved



Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 250,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 250,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	250,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17292		
<b>Mechanism Name:</b>	APHL Lab Follow on - (GH001097)		
<b>Prime Partner Name:</b>	Association of Public Health Laboratories		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	50,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details



<b>Mechanism ID: 17293</b>	<b>Mechanism Name: MDH Kagera - (GH001179)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Management development for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 15,098,193</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 11,067,460</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 26,165,653</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	15,098,193

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	130,000
Focus Area:	Training of health workers and community outreach workers



Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs
Gender: GBV	1,000,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Human Resources for Health	1,300,000
Food and Nutrition: Policy, Tools, and Service Delivery	200,000
Economic Strengthening	1,000,000

**Budget Code Information**

<b>Mechanism ID:</b> 17293			
<b>Mechanism Name:</b> MDH Kagera - (GH001179)			
<b>Prime Partner Name:</b> Management development for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	2,430,165	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	802,435	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	36,906	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	771,540	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	168,561	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	210,141	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	182,341	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	9,332,712	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,163,392	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	11,446
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	216,917
PMTCT_ART_DSD	New on ART	7,929
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,517
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	216,917
PMTCT_STAT_DSD	By Age (Denominator): 20-24	229,139
PMTCT_STAT_DSD	By Number of known positives: 20-24	4,697
PMTCT_STAT_DSD	By Number of new positives: 20-24	7,375
PMTCT_STAT_DSD	By Number of new negative: 20-24	202,806
PMTCT_STAT_DSD	By Age (Numerator): 20-24	135,287
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	3,607
KP_MAT_DSD	Sex: Male	2,885
KP_MAT_DSD	Sex: Female	722
KP_MAT_DSD	Sum of Sex disaggregates	3,607
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	165,709
VMMC_CIRC_DSD	By Age: 10-14	94,334
VMMC_CIRC_DSD	By Age: 15-19	42,538
VMMC_CIRC_DSD	By Age: 20-24	22,111
VMMC_CIRC_DSD	By Age: 25-29	6,726
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	158,983
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	165,709
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	165,709



HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,407,600
HTC_TST_DSD	By Test Result: Positive	53,973
HTC_TST_DSD	Sum of Test Result disaggregates	53,973
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	9,971
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	196
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	6,648
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	130
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	9,184
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	198
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	12,186
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	16,026
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	404
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	10,739
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	125
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	19,718
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,460
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	22,922



	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	610
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	47,567
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	6,501
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	34,236
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	2,728
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	6,870
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,007
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	5,895
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	989
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	5,161
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	82,219
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	750
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	81,250
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	839
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	70,795
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other	782



	PITC: <15, Male, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	353,802
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	17,730
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	239,302
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	9,385
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	2,710
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	53
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <15, Negative	45,775
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	888
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	35,505
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	698
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	6,645
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	130
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	4,432
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	86
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	10,114
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	218
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	6,739
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	145



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	203,947
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	7,418
GEND_GBV_DSD	Number of people receiving post-GBV care	23,342
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	15,614
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	7,722
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	0
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1,727
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	851
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	1,568
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	771
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	2,495
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	1,247
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1,919
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	949
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,458
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	718
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	1,408
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	686
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,169
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	590
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	957
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	466
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	1,388
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	682
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	1,161
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	567
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	160
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	72



GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	129
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	61
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	11,437
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	127
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	9,575
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	56
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,679
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	282,688
TX_CURR_DSD	Age/Sex: 15-19 Male	612
TX_CURR_DSD	Age/Sex: 15-19 Female	956
TX_CURR_DSD	Sum of age/sex disaggregates	1,568
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,945
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	57,822
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6,202
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	144,353
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	12,147
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	202,175
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	214,322
TX_CURR_DSD	Age/Sex: <1	73
TX_CURR_DSD	Age/Sex: <1-9	2,312
TX_CURR_DSD	Age/Sex: 10-14 Male	975
TX_CURR_DSD	Age/Sex: 10-14 Female	992
TX_CURR_DSD	Age/Sex: 20-24 Male	447
TX_CURR_DSD	Age/Sex: 25-49 Male	10,085
TX_CURR_DSD	Age/Sex: 50+ Male	4,760
TX_CURR_DSD	Age/Sex: 20-24 Female	2,224
TX_CURR_DSD	Age/Sex: 25-49 Female	37,633



TX_CURR_DSD	Age/Sex: 50+ Female	7,270
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	69,672
TX_NEW_DSD	By Age/Sex: <1	249
TX_NEW_DSD	By Age/Sex: 1-9	1,028
TX_NEW_DSD	By Age/Sex: 10-14 Male	179
TX_NEW_DSD	By Age/Sex: 15-19 Male	161
TX_NEW_DSD	By Age/Sex: 20-24 Male	230
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,769
TX_NEW_DSD	By Age/Sex: 50+ Male	805
TX_NEW_DSD	By Age/Sex: 10-14 Female	239
TX_NEW_DSD	By Age/Sex: 15-19 Female	371
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,612
TX_NEW_DSD	By Age/Sex: 25-49 Female	10,090
TX_NEW_DSD	By Age/Sex: 50+ Female	1,119
TX_NEW_DSD	Sum of Age/Sex disaggregates	18,575
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,763
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	14,259
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,945
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	31,806
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	49,773
TX_NEW_DSD	Pregnancy status	12,721
TX_NEW_DSD	Breastfeeding status	2,872
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	189,656
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	211,958
TX_PVLS_DSD	Numerator: Indication: Routine	170,706
TX_PVLS_DSD	Numerator: Indication: Targeted	18,950
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male	538



	Targeted	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	4,890
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	553
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	12,966
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	4,864
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	44,506
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	5,002
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	115,823
TX_PVLS_DSD	Denominator: Indication: Routine	190,740
TX_PVLS_DSD	Denominator: Indication: Targeted	21,185
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	596
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	5,494
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	633
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	14,461
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	5,442
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	49,880
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5,588
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	127,132
TX_PVLS_DSD	Undocumented Test Indication	0



TX_PVLS_DSD	Unknown Age, Targeted, Male	1
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	92,613
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	108,896
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,817
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,035
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,926
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	69,818
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,299
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20,060
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,416
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	82,121



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	21,849
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	43,694
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,739
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	2,589
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	15,715
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	23,560
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	43,604
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	853
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,292
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	7,850
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	11,878
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	21,849
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	6,719
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	268,785
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	242
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	378
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	2,472
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	3,594



TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	10,760
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	16,127
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	96,378
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	145,099
TX_TB_DSD	Denominator: By Screen Result: Negative	262,005
TX_TB_DSD	Denominator: By Screen Result: Positive	6,717
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	36

### Implementing Mechanism Details

<b>Mechanism ID: 17296</b>	<b>Mechanism Name: CDC PPP Management - (GH001531)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Cardno Emerging Markets	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,420,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,420,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,420,000

### Cross-Cutting Budget Attribution(s)

Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation



**Budget Code Information**

<b>Mechanism ID:</b> 17296			
<b>Mechanism Name:</b> CDC PPP Management - (GH001531)			
<b>Prime Partner Name:</b> Cardno Emerging Markets			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	670,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	250,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 17300</b>		<b>Mechanism Name: NIMR Follow On - (GH001633)</b>	
Funding Agency: HHS/CDC		Procurement Type: Cooperative Agreement	
Prime Partner Name: National Institute for Medical Research			
Agreement Start Date: Redacted		Agreement End Date: Redacted	
TBD: No		New Mechanism: No	
Global Fund / Multilateral Engagement: N/A			
G2G: Yes		Managing Agency: HHS/CDC	
<b>Total All Funding Sources: 800,000</b>		<b>Total Mechanism Pipeline: N/A</b>	
<b>Applied Pipeline Amount: 0</b>			
<b>Total All Funding Sources and Applied Pipeline Amount: 800,000</b>			



Funding Source	Funding Amount
GHP-State	800,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17300			
<b>Mechanism Name:</b> NIMR Follow On - (GH001633)			
<b>Prime Partner Name:</b> National Institute for Medical Research			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	275,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	225,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID:</b> 17304	<b>Mechanism Name:</b> University Partnership Field Epidemiology Expansion - (GH001304)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement



Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 500,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	500,000

**Cross-Cutting Budget Attribution(s)**

Human Resources for Health	375,000
----------------------------	---------

**Budget Code Information**

<b>Mechanism ID:</b> 17304			
<b>Mechanism Name:</b> University Partnership Field Epidemiology Expansion - (GH001304)			
<b>Prime Partner Name:</b> University of Washington			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	200,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	300,000	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	15
HRH_PRE	By Graduates: Nurses	1
HRH_PRE	By Graduates: Laboratory professionals	1
HRH_PRE	By Graduates: Other	13
HRH_PRE	Sum of Graduates disaggreagtes	15

**Implementing Mechanism Details**

<b>Mechanism ID: 17305</b>	<b>Mechanism Name: Twinning follow On (U7HA04128)</b>
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,350,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,350,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,350,000

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Capacity building
Sub Area:	Operation Research
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research

**Budget Code Information**

<b>Mechanism ID:</b>	17305		
<b>Mechanism Name:</b>	Twinning follow On (U7HA04128)		
<b>Prime Partner Name:</b>	American International Health Alliance		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	400,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,050,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	300,000	0

**Implementing Mechanism Indicator Information**



Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	3,203
HRH_PRE	By Graduates: Nurses	3,203
HRH_PRE	Sum of Graduates disaggregated	3,203

### Implementing Mechanism Details

<b>Mechanism ID: 17316</b>	<b>Mechanism Name: UNICEF Follow on - (GH001619)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 510,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 510,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	510,000

### Cross-Cutting Budget Attribution(s)

Gender: GBV	40,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	20,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: GBV	40,000
Focus Area:	Post GBV Care
Sub Area:	Monitoring and Evaluation
Sub Area:	Capacity building
Gender: Gender Equality	20,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation



### Budget Code Information

<b>Mechanism ID:</b>	17316		
<b>Mechanism Name:</b>	UNICEF Follow on - (GH001619)		
<b>Prime Partner Name:</b>	United Nations Children's Fund		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	360,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17358</b>	<b>Mechanism Name: Kizazi Kipya</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 11,324,762</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 24,000,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 35,324,762</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	11,324,762



### Cross-Cutting Budget Attribution(s)

Gender: GBV	1,447,642
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	2,920,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Water	1,460,000

### Budget Code Information

<b>Mechanism ID:</b>	17358		
<b>Mechanism Name:</b>	Kizazi Kipya		
<b>Prime Partner Name:</b>	Pact, Inc.		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	11,324,762	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	766,969
OVC_SERV_DSD	Age/Sex: 10-14 Male	70,235
OVC_SERV_DSD	Age/Sex: 15-17 Male	33,376
OVC_SERV_DSD	By: Age/sex: Male 18-24	27,458
OVC_SERV_DSD	By: Age/sex: Male 25+	83,297
OVC_SERV_DSD	Age/Sex: 10-14 Female	70,164



OVC_SERV_DSD	Age/Sex: 15-17 Female	33,778
OVC_SERV_DSD	By: Age/sex: 18-24 Female	29,431
OVC_SERV_DSD	By: Age/sex: 25+ Female	81,531
OVC_SERV_DSD	Sum of Age/Sex disaggregates	207,553
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	8,000
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	9,032
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	5,727
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	8,005
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	12,142
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	7,965
OVC_SERV_DSD	Age/Sex: <1	36,010
OVC_SERV_DSD	Age/Sex: 1-9	301,668
OVC_SERV_DSD	Program Completion: Active	613,467
OVC_SERV_DSD	Program Completion: Graduation	76,751
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	76,751

### Implementing Mechanism Details

<b>Mechanism ID: 17409</b>	<b>Mechanism Name: Maternal and Child Survival Program (MCSP)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
-------------------------------------	--------------------------------------



<b>Applied Pipeline Amount: 1,600,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,600,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17409		
<b>Mechanism Name:</b>	Maternal and Child Survival Program (MCSP)		
<b>Prime Partner Name:</b>	JHPIEGO		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	0	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	896
HRH_PRE	By Graduates: Doctors	0



HRH_PRE	By Graduates: Nurses	323
HRH_PRE	By Graduates: Midwives	573
HRH_PRE	By Graduates: Social service workers	0
HRH_PRE	By Graduates: Laboratory professionals	0
HRH_PRE	By Graduates: Other	0
HRH_PRE	Sum of Graduates disaggregates	896

### Implementing Mechanism Details

<b>Mechanism ID: 17416</b>	<b>Mechanism Name: USAID Social Enterprise Support Activity (USES A)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: T-MARC Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 0</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 500,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	0

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	17416
<b>Mechanism Name:</b>	USAID Social Enterprise Support Activity (USES A)
<b>Prime Partner Name:</b>	T-MARC Tanzania



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17420</b>	<b>Mechanism Name: Challenge TB</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: KNCV Tuberculosis Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 1,351,458</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,351,458</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,351,458

### Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	60,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Renovation	120,000
Human Resources for Health	205,832



### Budget Code Information

<b>Mechanism ID:</b> 17420			
<b>Mechanism Name:</b> Challenge TB			
<b>Prime Partner Name:</b> KNCV Tuberculosis Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	51,458	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	23,302
HTC_TST_DSD	By Test Result: Positive	7,948
HTC_TST_DSD	Sum of Test Result disaggregates	7,948
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	5,050
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	3,832
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	10,304
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	4,114
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	23,302
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	23,302



TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14,423
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8,879
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	14,423
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	8,878
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	7,949
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	7,953
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,118
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3,831
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with	0



	documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4,118
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3,831

### Implementing Mechanism Details

<b>Mechanism ID: 17985</b>	<b>Mechanism Name: TBD Blood Safety TA - (GH001565)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Africa Society for Blood Transfusions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 320,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 320,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	320,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information



<b>Mechanism ID: 17985</b>			
<b>Mechanism Name: TBD Blood Safety TA - (GH001565)</b>			
<b>Prime Partner Name: Africa Society for Blood Transfusions</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	320,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17986</b>	<b>Mechanism Name: Local FOA TBD1 - (GH002021)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ariel Glaser Pediatric AIDS Healthcare Initiative	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 33,161,263</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 33,161,263</b>	
Funding Source	Funding Amount
GHP-State	33,161,263

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	200,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions



	for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	150,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Focus Area:	Collection and use of strategic information on SWs and clients
Gender: GBV	750,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Gender: Gender Equality	100,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Human Resources for Health	1,000,000

**Budget Code Information**

<b>Mechanism ID:</b> 17986			
<b>Mechanism Name:</b> Local FOA TBD1 - (GH002021)			
<b>Prime Partner Name:</b> Ariel Glaser Pediatric AIDS Healthcare Initiative			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	1,827,651	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	418,761	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,697,382	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	333,333	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	IDUP	108,590	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	6,177,754	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	21,017,976	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Treatment	PDX	1,579,816	0
-----------	-----	-----------	---

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	15,931
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	392,761
PMTCT_ART_DSD	New on ART	9,460
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	6,471
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	392,761
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	411,058
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	4,878
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	12,256
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	375,917
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	389,372
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,074,549
HTC_TST_DSD	By Test Result: Positive	74,993
HTC_TST_DSD	Sum of Test Result disaggregates	74,993
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	14,884
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	226
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	14,256



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	253
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	246
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	56
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	1,075
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	508
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	222
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	202
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	9



HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1,271
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	24,639
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	404
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	23,260
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	382
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	22,278
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	377
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	11,673
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,163
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	6,459
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	671
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	51,899
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	5,328
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	13,245



HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,360
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	194,252
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	24,307
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	98,590
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	12,603
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	49,665
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	6,282
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	42,351
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	5,502
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Negative	2,296
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	40,049
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	676
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	38
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	8



HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	524
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	71
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	289
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	9,188
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	150
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	10,723
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	222
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	10,542
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	198
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	578
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	198
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	358
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	3,081
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	1,144



HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	694
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	241
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	12,604
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	5,001
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	6,374
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	2,552
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3,253
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	1,265
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	2,810
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1,113
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	982
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	18,962
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	370
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	4,085
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	67



HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	84,291
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	4,080
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	277,666
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	12,469
GEND_GBV_DSD	Number of people receiving post-GBV care	31,257
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	14,534
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	4,841
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	4,841
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1,469
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	193
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	1
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	311
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	356
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	54
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	398
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	55
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	216
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	31
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,887
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	307
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	417
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	8,901
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	1,244
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	4,884



GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	686
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	1,908
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	181
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	1,758
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	172
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	860
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	33,903
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	50
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	476
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	304



	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2,159
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	19,400
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1,438
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	12,834
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	15,889
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	251
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	10,410
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	172
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	5,056
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	281,183
TX_CURR_DSD	Age/Sex: 15-19 Male	2,747
TX_CURR_DSD	Age/Sex: 15-19 Female	1,722
TX_CURR_DSD	Sum of age/sex disaggregates	4,469
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,463
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	68,248



TX_CURR_DSD	Aggregated Age/Sex: <15 Female	9,955
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	118,096
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	12,418
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	186,344
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	198,762
TX_CURR_DSD	Age/Sex: <1	83
TX_CURR_DSD	Age/Sex: <1-9	2,395
TX_CURR_DSD	Age/Sex: 10-14 Male	1,057
TX_CURR_DSD	Age/Sex: 10-14 Female	624
TX_CURR_DSD	Age/Sex: 20-24 Male	1,579
TX_CURR_DSD	Age/Sex: 25-49 Male	16,665
TX_CURR_DSD	Age/Sex: 50+ Male	5,867
TX_CURR_DSD	Age/Sex: 20-24 Female	8,577
TX_CURR_DSD	Age/Sex: 25-49 Female	34,061
TX_CURR_DSD	Age/Sex: 50+ Female	6,509
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	83,894
TX_NEW_DSD	By Age/Sex: <1	40
TX_NEW_DSD	By Age/Sex: 1-9	298
TX_NEW_DSD	By Age/Sex: 10-14 Male	134
TX_NEW_DSD	By Age/Sex: 15-19 Male	144
TX_NEW_DSD	By Age/Sex: 20-24 Male	200
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,198
TX_NEW_DSD	By Age/Sex: 50+ Male	686
TX_NEW_DSD	By Age/Sex: 10-14 Female	144
TX_NEW_DSD	By Age/Sex: 15-19 Female	390
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,072
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,764
TX_NEW_DSD	By Age/Sex: 50+ Female	691
TX_NEW_DSD	Sum of Age/Sex disaggregates	9,423
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	896
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	24,491



TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2,861
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	45,884
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	74,132
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	217,788
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	243,080
TX_PVLS_DSD	Numerator: Indication: Routine	195,928
TX_PVLS_DSD	Numerator: Indication: Targeted	21,860
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	314
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	7,402
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	1,050
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	13,078
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	2,506
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	66,204
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	8,824
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	118,388
TX_PVLS_DSD	Denominator: Indication: Routine	218,617
TX_PVLS_DSD	Denominator: Indication: Targeted	24,163
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	12
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	1
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	281



TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	8,229
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	1,056
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	14,664
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	4,379
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	72,460
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	12,483
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	129,241
TX_PVLS_DSD	<15, Routine, Unknown Sex	9
TX_PVLS_DSD	<15, Targeted, Unknown Sex	1
TX_PVLS_DSD	15+, Routine, Unknown Sex	94
TX_PVLS_DSD	15+, Targeted, Unknown Sex	10
TX_PVLS_DSD	Unknown Age, Routine, Female	73
TX_PVLS_DSD	Unknown Age, Routine, Male	43
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	8
TX_PVLS_DSD	Unknown Age, Targeted, Male	1
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,185
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,251



TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	110
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,851
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	376
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,847
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	115
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,875
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	410
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,839
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting	24,557



	period	
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	49,135
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,930
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	2,903
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	17,717
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	26,582
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	49,089
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	948
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	1,438
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	8,860
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	13,311
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	24,557
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	6,554
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	266,543
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	244
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	372
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	2,335
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	3,601
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	10,698
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	16,008
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	96,015
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	143,808
TX_TB_DSD	Denominator: By Screen Result: Negative	257,356



TX_TB_DSD	Denominator: By Screen Result: Positive	7,020
-----------	---	-------

**Implementing Mechanism Details**

<b>Mechanism ID: 17987</b>	<b>Mechanism Name: TBD Institutional Capacity Building TA - (GH001929)</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Management Sciences for Health		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

<b>Total All Funding Sources: 1,890,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,890,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,890,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17987		
<b>Mechanism Name:</b>	TBD Institutional Capacity Building TA - (GH001929)		
<b>Prime Partner Name:</b>	Management Sciences for Health		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Governance and Systems	HVSI	800,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	710,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	100,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	280,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17988</b>	<b>Mechanism Name: TBD Surveillance TA - (GH000977)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 2,250,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 2,250,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,250,000



**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b> 17988			
<b>Mechanism Name:</b> TBD Surveillance TA - (GH000977)			
<b>Prime Partner Name:</b> University of California at San Francisco			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	400,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	1,150,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	300,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the	26



	reporting period, by select cadre	
HRH_PRE	By Graduates: Other	26
HRH_PRE	Sum of Graduates disaggreagtes	26

**Implementing Mechanism Details**

<b>Mechanism ID: 17990</b>	<b>Mechanism Name: TBD Clinical TA (International) - (GH001950)</b>	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: University of Maryland		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	

<b>Total All Funding Sources: 3,550,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,550,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,550,000

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation

**Budget Code Information**



<b>Mechanism ID: 17990</b>			
<b>Mechanism Name: TBD Clinical TA (International) - (GH001950)</b>			
<b>Prime Partner Name: University of Maryland</b>			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,350,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 17991</b>	<b>Mechanism Name: TBD Comprehensive High Impact HIV Prevention IP (Local) - (GH002018)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 10,137,499</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 10,137,499</b>	
Funding Source	Funding Amount
GHP-State	10,137,499

### Cross-Cutting Budget Attribution(s)

(No data provided.)



**Budget Code Information**

<b>Mechanism ID:</b> 17991			
<b>Mechanism Name:</b> TBD Comprehensive High Impact HIV Prevention IP (Local) - (GH002018)			
<b>Prime Partner Name:</b> Columbia University			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	5,883,992	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	3,027,549	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	IDUP	425,958	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	800,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	5,648
PrEP_NEW_DSD	Female 15-19	166
PrEP_NEW_DSD	Female 20-24	681
PrEP_NEW_DSD	Female 25-49	2,660
PrEP_NEW_DSD	Female 50+	166
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	83,856



PP_PREV_DSD	Age/sex: 15-19 Male	0
PP_PREV_DSD	Age/sex: 20-24 Male	0
PP_PREV_DSD	Age/sex: 15-19 Female	33,540
PP_PREV_DSD	Age/sex: 20-24 Female	50,317
PP_PREV_DSD	Sum of Age/Sex disaggregates	83,857
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	55,104
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	5,765
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	44,528
KP_PREV_DSD	By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,331
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	480
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	522,785
HTC_TST_DSD	By Test Result: Positive	13,022
HTC_TST_DSD	Sum of Test Result disaggregates	13,022
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile	39,778



	Testing: <15, Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	567
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	32,550
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	448
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	108,424
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	3,462
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	88,722
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	2,823
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	59,558
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	838
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	48,791
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	690
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	72,463
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	2,321
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	59,340
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	1,879

### Implementing Mechanism Details

<b>Mechanism ID: 17992</b>	<b>Mechanism Name: TBD Multilateral AIDS Sector</b>
----------------------------	---



	<b>Follow On</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 100,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 100,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	100,000

**Cross-Cutting Budget Attribution(s)**

(No data provided.)

**Budget Code Information**

<b>Mechanism ID:</b>	17992		
<b>Mechanism Name:</b>	TBD Multilateral AIDS Sector Follow On		
<b>Prime Partner Name:</b>	UNAIDS - Joint United Nations Programme on HIV/AIDS		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	100,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)



### Implementing Mechanism Details

<b>Mechanism ID: 18056</b>	<b>Mechanism Name: Comprehensive Platform for Integrated Communication Interventions (CPICI)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,250,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 2,000,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 3,250,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	1,250,000

### Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	125,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	125,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	400,000



Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	600,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building

**Budget Code Information**

<b>Mechanism ID:</b>	18056		
<b>Mechanism Name:</b>	Comprehensive Platform for Integrated Communication Interventions (CPICI)		
<b>Prime Partner Name:</b>	FHI 360		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HKID	150,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	600,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	300,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18058</b>	<b>Mechanism Name: Strengthening Health Outcomes through the Private Sector in Tanzania (SHOPS+)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 1,300,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 1,300,000</b>	
Funding Source	Funding Amount
GHP-State	1,300,000

### Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	300,000
Focus Area:	Increase gender-equitable access to income and



	productive resources, including education
Sub Area:	Capacity building
Human Resources for Health	200,000
Economic Strengthening	800,000

### Budget Code Information

<b>Mechanism ID:</b>	18058		
<b>Mechanism Name:</b>	Strengthening Health Outcomes through the Private Sector in Tanzania		
<b>Prime Partner Name:</b>	(SHOPS+)		
	Abt Associates		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVOP	450,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	700,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	150,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18060</b>	<b>Mechanism Name: Boresha Afya Northern Zone</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
<b>Total All Funding Sources: 8,572,436</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 8,000,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 16,572,436</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	8,572,436

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	1,760,752
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	1,565,952
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection



Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	100,000

**Budget Code Information**

<b>Mechanism ID: 18060</b>			
<b>Mechanism Name: Boresha Afya Northern Zone</b>			
<b>Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	163,864	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	728,591	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	169,463	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	120,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	1,112,255	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	1,778,704	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	3,378,802	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	1,120,757	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	6,456
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	228,560
PMTCT_ART_DSD	New on ART	3,461
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,995
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	228,560



	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	242,127
PMTCT_STAT_DSD	By Age (Denominator): 25-49	1,546
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	2,831
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 25-49	15
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	3,977
PMTCT_STAT_DSD	By Number of new positives: 25-49	22
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	220,234
PMTCT_STAT_DSD	By Number of new negative: 25-49	1,432
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	226,034
PMTCT_STAT_DSD	By Age (Numerator): 25-49	1,469
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,184,914
HTC_TST_DSD	By Test Result: Positive	46,908
HTC_TST_DSD	Sum of Test Result disaggregates	46,908
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	20,507
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	145
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	23,204
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	195
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	5,377
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	300
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	4,030
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient:	229



	15+, Male, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	29,523
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	310
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	34,685
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	424
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	408,970
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	18,671
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	297,686
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	13,984
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	8,264
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	95
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	13,698
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	121
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	15,240
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	150
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	27,653
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	4,663
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	20,374
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	3,539



	Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	1,692
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	20
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	220,602
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	3,976
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
GEND_GBV_DSD	Number of people receiving post-GBV care	11,124
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7,466
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,196
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	456
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	10
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	19
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional	9



	Violence	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	6,435
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	27
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	5,053
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	102
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,253
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	153,642
TX_CURR_DSD	Age/Sex: 15-19 Male	63
TX_CURR_DSD	Age/Sex: 15-19 Female	189
TX_CURR_DSD	Sum of age/sex disaggregates	252
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	5,137
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	39,570
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	5,338
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	94,557
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	10,475
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	134,127
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	144,602
TX_CURR_DSD	Age/Sex: <1	50
TX_CURR_DSD	Age/Sex: <1-9	387
TX_CURR_DSD	Age/Sex: 10-14 Male	68
TX_CURR_DSD	Age/Sex: 10-14 Female	83
TX_CURR_DSD	Age/Sex: 20-24 Male	63
TX_CURR_DSD	Age/Sex: 25-49 Male	2,010
TX_CURR_DSD	Age/Sex: 50+ Male	517
TX_CURR_DSD	Age/Sex: 20-24 Female	500
TX_CURR_DSD	Age/Sex: 25-49 Female	4,374
TX_CURR_DSD	Age/Sex: 50+ Female	726



TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	47,703
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	966
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	13,664
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,170
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	31,903
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	47,703
TX_NEW_DSD	Pregnancy status	3,406
TX_NEW_DSD	Breastfeeding status	926
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	103,589
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	115,102
TX_PVLS_DSD	Numerator: Indication: Routine	93,240
TX_PVLS_DSD	Numerator: Indication: Targeted	10,349
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	3,024
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	365
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	737
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	59
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	353
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,808
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	375
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	6,787
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	3,272



TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	25,095
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	3,424
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	60,932
TX_PVLS_DSD	Denominator: Indication: Routine	103,482
TX_PVLS_DSD	Denominator: Indication: Targeted	11,485
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	3,480
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	416
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	870
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	75
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	388
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	3,126
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	397
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	7,556
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,655
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	28,070
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,783
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	67,977
TX_PVLS_DSD	<15, Routine, Unknown Sex	1
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	22
TX_PVLS_DSD	15+, Targeted, Unknown Sex	2



TX_PVLS_DSD	<15, Routine, Unknown Sex	24
TX_PVLS_DSD	<15, Targeted, Unknown Sex	3
TX_PVLS_DSD	15+, Routine, Unknown Sex	420
TX_PVLS_DSD	15+, Targeted, Unknown Sex	44
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	1
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	24,980
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	29,375
TX_RET_DSD	Numerator by Status: Pregnant	456
TX_RET_DSD	Numerator by Status: Breastfeeding	2,409
TX_RET_DSD	Denominator by Status: Pregnant	545
TX_RET_DSD	Denominator by Status: Breastfeeding	2,843
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	917
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,681
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,607
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	15,694
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,076
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total	7,860



	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,895
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18,467
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	13,875
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	27,740
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,095
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,649
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	10,006
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	14,970
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	27,738
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	2
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	524
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	804
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,036



TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	7,481
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	13,871
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	4
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	3,646
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	145,969
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	111
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	181
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	1,332
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	1,974
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	5,866
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	8,753
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	52,468
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	78,687
TX_TB_DSD	Denominator: By Screen Result: Negative	141,800
TX_TB_DSD	Denominator: By Screen Result: Positive	3,624
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	8

### Implementing Mechanism Details

<b>Mechanism ID: 18061</b>	<b>Mechanism Name: Health Policy Plus (HP+)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	



Funding Source	Funding Amount
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	40,000
Focus Area:	GBV Prevention
Sub Area:	Operation Research
Sub Area:	Collection and Use of Gender-related Strategic Information
Key Populations: MSM and TG	40,000
Focus Area:	Collection and use of strategic information
Key Populations: FSW	40,000
Focus Area:	Collection and use of strategic information on SWs and clients
Food and Nutrition: Commodities	40,000
Economic Strengthening	40,000
Human Resources for Health	40,000
Food and Nutrition: Policy, Tools, and Service Delivery	40,000
Education	40,000

**Budget Code Information**

<b>Mechanism ID:</b> 18061			
<b>Mechanism Name:</b> Health Policy Plus (HP+)			
<b>Prime Partner Name:</b> Futures Group			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	250,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	PDTX	150,000	0
-----------	------	---------	---

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18072</b>	<b>Mechanism Name: Results-based Financing</b>
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 3,700,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 1,800,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,500,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	3,700,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	400,000
----------------------------	---------

### Budget Code Information

<b>Mechanism ID:</b>	<b>18072</b>
<b>Mechanism Name:</b>	<b>Results-based Financing</b>
<b>Prime Partner Name:</b>	<b>New Partner</b>



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	500,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,200,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18130</b>	<b>Mechanism Name: TBD</b>
Funding Agency: DOD	Procurement Type: Contract
Prime Partner Name: Research Triangle International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 49,536</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 148,914</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 198,450</b>	
Funding Source	Funding Amount
GHP-State	49,536

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b>	18130		
<b>Mechanism Name:</b>	TBD		
<b>Prime Partner Name:</b>	Research Triangle International		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HVSI	49,536	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18131</b>	<b>Mechanism Name: VMMC Follow on - (GH002031)</b>
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,113,995</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 6,113,995</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,113,995

### Cross-Cutting Budget Attribution(s)

(No data provided.)



### Budget Code Information

<b>Mechanism ID:</b> 18131			
<b>Mechanism Name:</b> VMMC Follow on - (GH002031)			
<b>Prime Partner Name:</b> IntraHealth International, Inc			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	6,113,995	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	320,509
VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	144,227
VMMC_CIRC_DSD	By Age: 15-19	99,358
VMMC_CIRC_DSD	By Age: 20-24	51,282
VMMC_CIRC_DSD	By Age: 25-29	25,642
VMMC_CIRC_DSD	By Age: 30-49	0
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	294,867
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	320,509
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	320,509
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	160,255
HTC_TST_DSD	By Test Result: Positive	2,724



HTC_TST_DSD	Sum of Test Result disaggregates	2,724
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	75,615
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	1,320
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	51,989
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	901
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	29,925
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	505
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0

### Implementing Mechanism Details

<b>Mechanism ID: 18170</b>	<b>Mechanism Name: Consolidated MOH Coag - (GH17-1722)</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health and Social Welfare, Tanzania	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



<b>Total All Funding Sources: 5,640,265</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 5,640,265</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	5,640,265

### Cross-Cutting Budget Attribution(s)

Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Collection and Use of Gender-related Strategic Information

### Budget Code Information

<b>Mechanism ID:</b>	18170		
<b>Mechanism Name:</b>	Consolidated MOH Coag - (GH17-1722)		
<b>Prime Partner Name:</b>	Ministry of Health and Social Welfare, Tanzania		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HBHC	110,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	935,480	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	530,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and	HVSI	825,000	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	310,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	697,644	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	440,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	262,141	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	630,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	650,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	250,000	0

**Implementing Mechanism Indicator Information**

Indicator Number	Label	2018
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	28,122
HTC_TST_DSD	By Test Result: Positive	10,911
HTC_TST_DSD	Sum of Test Result disaggregates	10,911
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+,	5,818



	Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	4,950
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	11,395
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	5,959
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	28,122
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	28,122
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	17,309
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10,813
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	10,906
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	10,906
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	5,962
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4,944

### Implementing Mechanism Details

<b>Mechanism ID: 18171</b>	<b>TBD: Yes</b>
----------------------------	-----------------



**REDACTED**

**Implementing Mechanism Details**

<b>Mechanism ID: 18198</b>	<b>Mechanism Name: Global Health Supply Chain-Procurement and Supply Management (GHSC-PSM)</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 119,213,235</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 119,213,235</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	119,213,235

**Cross-Cutting Budget Attribution(s)**

Condom procurement	2,471,739
--------------------	-----------

**Budget Code Information**

<b>Mechanism ID:</b>	18198		
<b>Mechanism Name:</b>	Global Health Supply Chain- Procurement and Supply Management (GHSC-PSM)		
<b>Prime Partner Name:</b>	Global Health Supply Chain Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HVTB	5,747,865	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	26,620	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	CIRC	5,238,741	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	19,106,438	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXD	70,112,159	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	18,981,412	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18200</b>	<b>Mechanism Name: Global Health Supply Chain-Technical Assistance (GHSC-TA)</b>
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Global Health Supply Chain Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 2,390,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 2,390,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	2,390,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	18200		
<b>Mechanism Name:</b>	Global Health Supply Chain- Technical Assistance (GHSC-TA)		
<b>Prime Partner Name:</b>	Global Health Supply Chain Program		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	1,590,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	500,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	300,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID: 18237</b>	<b>Mechanism Name: Boresha Afya Southern Zone</b>
<b>Funding Agency: USAID</b>	<b>Procurement Type: Cooperative Agreement</b>
<b>Prime Partner Name: Deloitte Consulting Limited</b>	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 6,982,486</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 10,000,000</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 16,982,486</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	6,982,486

### Cross-Cutting Budget Attribution(s)

Gender: GBV	1,435,068
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	1,398,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building

Approved



Sub Area:	Monitoring and Evaluation
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Water	72,500

**Budget Code Information**

<b>Mechanism ID:</b>	18237		
<b>Mechanism Name:</b>	Boresha Afya Southern Zone		
<b>Prime Partner Name:</b>	Deloitte Consulting Limited		
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>



Care	HBHC	0	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	HVTB	802,965	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Care	PDCS	204,846	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	HLAB	120,000	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	HVCT	461,648	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Prevention	MTCT	5,538	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	HTXS	4,495,800	0
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Treatment	PDTX	891,689	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	7,806
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	126,217



PMTCT_ART_DSD	New on ART	5,037
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,769
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	126,217
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	117,276
PMTCT_STAT_DSD	By Age (Denominator): 25-49	18,807
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	2,816
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,009
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	3,388
PMTCT_STAT_DSD	By Number of new positives: 25-49	1,021
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	101,608
PMTCT_STAT_DSD	By Number of new negative: 25-49	15,836
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	76,778
PMTCT_STAT_DSD	By Age (Numerator): 25-49	17,777
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	796,904
HTC_TST_DSD	By Test Result: Positive	49,058
HTC_TST_DSD	Sum of Test Result disaggregates	49,058
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	22,551
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	342
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	21,670
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	323
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	13,864
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	1,052
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient:	6,153



	15+, Male, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	482
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	35,230
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	669
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	34,128
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	657
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	285,864
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	22,060
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	131,494
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	10,678
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	7,394
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	80
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	15,188
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	205
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	14,560
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	198
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	18,697
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	5,594
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	8,686



	Male, Negative	
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	2,633
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	2,686
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	14
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	118,248
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	4,425
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
GEND_GBV_DSD	Number of people receiving post-GBV care	22,561
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	20,079
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,258
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,237
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	0
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0



TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	7,769
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	119
PMTCT_EID_DSD	Unknown, <= 2 months	15
PMTCT_EID_DSD	Unknown, 2 - 12 months	5
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	5,756
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	84
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,790
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	182,681
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	6,471
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	52,247
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	6,282
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	117,676
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	12,753
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	169,923
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	182,676
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	50,576
TX_NEW_DSD	By Age/Sex: 25-49 Female	26
TX_NEW_DSD	Sum of Age/Sex disaggregates	26
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1,565



TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	14,467
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1,555
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	32,946
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	50,533
TX_NEW_DSD	Pregnancy status	2,714
TX_NEW_DSD	Breastfeeding status	350
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	123,571
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	137,674
TX_PVLS_DSD	Numerator: Indication: Routine	111,208
TX_PVLS_DSD	Numerator: Indication: Targeted	12,363
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	2,371
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	180
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	125
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	116
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	431
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	3,535
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	430
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	7,974
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	4,032
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	31,899
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15	3,755



	Female Routine	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	71,286
TX_PVLS_DSD	Denominator: Indication: Routine	123,840
TX_PVLS_DSD	Denominator: Indication: Targeted	13,791
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	2,668
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	225
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	133
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	110
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	468
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	3,944
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	446
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	8,873
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	4,431
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	35,440
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	4,253
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	79,726
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0



TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	3
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	46
TX_PVLS_DSD	15+, Targeted, Unknown Sex	5
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	1
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	1
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0



TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	27,646
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	32,470
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,150
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,092
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,227
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,166
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,320
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,497
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	1,411



	including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20,209
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	15,287
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	30,580
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	1,195
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	1,815
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	11,036
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	16,491
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	30,501
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	581
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	891
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	5,545
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	8,263
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	15,282
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	4,368



TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	174,265
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	153
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	233
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	1,587
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	2,336
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	4,901
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	7,357
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Female	44,339
TX_TB_DSD	Denominator: By Aggregated Age/Sex: 15+, Male	66,191
TX_TB_DSD	Denominator: By Screen Result: Negative	169,804
TX_TB_DSD	Denominator: By Screen Result: Positive	4,348
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	0

### Implementing Mechanism Details

<b>Mechanism ID: 18243</b>	<b>Mechanism Name: AFENET Follow-On</b>
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Field Epidemiology Network	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources: 200,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	



<b>Total All Funding Sources and Applied Pipeline Amount: 200,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	200,000

### Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
----------------------------	---------

### Budget Code Information

<b>Mechanism ID: 18243</b>			
<b>Mechanism Name: AFENET Follow-On</b>			
<b>Prime Partner Name: African Field Epidemiology Network</b>			
<b>Strategic Area</b>	<b>Budget Code</b>	<b>Planned Amount</b>	<b>On Hold Amount</b>
Governance and Systems	OHSS	200,000	0

### Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	12
HRH_PRE	By Graduates: Doctors	4
HRH_PRE	By Graduates: Nurses	2
HRH_PRE	By Graduates: Laboratory professionals	4
HRH_PRE	By Graduates: Other	2
HRH_PRE	Sum of Graduates disaggregated	12



**Implementing Mechanism Details**

<b>Mechanism ID: 18488</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18489</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

**Implementing Mechanism Details**

<b>Mechanism ID: 18621</b>	<b>Mechanism Name: Human Rights Support Mechanism (HRSM)</b>
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

Gender: GBV	40,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	40,000



Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Sub Area:	Operation Research
Food and Nutrition: Commodities	40,000

Approved



Food and Nutrition: Policy, Tools, and Service Delivery	40,000
Water	40,000
Economic Strengthening	40,000
Human Resources for Health	40,000
Education	40,000

### Budget Code Information

<b>Mechanism ID:</b> 18621			
<b>Mechanism Name:</b> Human Rights Support Mechanism (HRSM)			
<b>Prime Partner Name:</b> New Partner			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	400,000	0

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

<b>Mechanism ID:</b> 18622	<b>Mechanism Name:</b> EQUIP
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Right to Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:
<b>Total All Funding Sources:</b> 400,000	<b>Total Mechanism Pipeline:</b> N/A
<b>Applied Pipeline Amount:</b> 0	



<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

**Cross-Cutting Budget Attribution(s)**

Key Populations: FSW	4,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Key Populations: MSM and TG	4,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance

**Budget Code Information**

<b>Mechanism ID:</b> 18622 <b>Mechanism Name:</b> EQUIP <b>Prime Partner Name:</b> Right to Care			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	400,000	0

**Implementing Mechanism Indicator Information**

(No data provided.)

**Implementing Mechanism Details**

<b>Mechanism ID: 18627</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	



### Implementing Mechanism Details

<b>Mechanism ID: 18628</b>	<b>TBD: Yes</b>
<b>REDACTED</b>	

### Implementing Mechanism Details

<b>Mechanism ID: 18629</b>	<b>Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)</b>
Funding Agency: HHS/HRSA	Procurement Type: Contract
Prime Partner Name: Health Research Inc./New York State Department of Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

<b>Total All Funding Sources: 400,000</b>	<b>Total Mechanism Pipeline: N/A</b>
<b>Applied Pipeline Amount: 0</b>	
<b>Total All Funding Sources and Applied Pipeline Amount: 400,000</b>	
<b>Funding Source</b>	<b>Funding Amount</b>
GHP-State	400,000

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Budget Code Information

<b>Mechanism ID:</b>	<b>18629</b>
<b>Mechanism Name:</b>	<b>Quality Improvement Capacity for Impact Project (QICIP)</b>
<b>Prime Partner Name:</b>	<b>Health Research Inc./New York State Department of Health</b>

Approved



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	400,000	0

### Implementing Mechanism Indicator Information

(No data provided.)



**Agency Information - Costs of Doing Business**  
**U.S. Agency for International Development**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		0		0	297,200	297,200
ICASS		0		0	965,000	965,000
Institutional Contractors		2,816,433		2,816,433	5,000,000	7,816,433
Management Meetings/Professional Development		0		0	412,000	412,000
Non-ICASS Administrative Costs		858,200		858,200	45,800	904,000
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		0		0	280,000	280,000
USG Staff Salaries and Benefits - Internationally Recruited		884,953		884,953	1,214,933	2,099,886
USG Staff Salaries and Benefits -		1,684,975		1,684,975	1,500,000	3,184,975



Locally Recruited						
<b>Total</b>	<b>0</b>	<b>6,244,561</b>	<b>0</b>	<b>6,244,561</b>	<b>9,714,933</b>	<b>15,959,494</b>

**U.S. Department of Defense**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		14,576		14,576	10,424	25,000
ICASS		243,640		243,640	156,360	400,000
Institutional Contractors		360,248		360,248	239,752	600,000
Management Meetings/Professional Development		27,880		27,880	52,120	80,000
Non-ICASS Administrative Costs		90,000		90,000	0	90,000
Staff Program Travel		176,520		176,520	208,480	385,000
USG Staff Salaries and Benefits - Internationally Recruited		336,577		336,577	271,023	607,600
USG Staff Salaries and Benefits -		426,560		426,560	104,240	530,800



Locally Recruited						
<b>Total</b>	<b>0</b>	<b>1,676,001</b>	<b>0</b>	<b>1,676,001</b>	<b>1,042,399</b>	<b>2,718,400</b>

**U.S. Department of Health and Human Services/Centers for Disease Control and Prevention**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing	190,000			190,000	0	190,000
Computers/IT Services	750,000	189,000		939,000	0	939,000
ICASS	1,228,500	40,000		1,268,500	0	1,268,500
Institutional Contractors	0	2,780,000		2,780,000	0	2,780,000
Management Meetings/Professional Development		30,000		30,000	0	30,000
Non-ICASS Administrative Costs		1,815,440		1,815,440	0	1,815,440
Staff Program Travel	0	1,110,600		1,110,600	0	1,110,600
USG Staff Salaries and Benefits - Internationally Recruited	450,250	375,423		825,673	1,841,784	2,667,457



USG Staff Salaries and Benefits - Locally Recruited	0	2,815,265		2,815,265	0	2,815,265
<b>Total</b>	<b>2,618,750</b>	<b>9,155,728</b>	<b>0</b>	<b>11,774,478</b>	<b>1,841,784</b>	<b>13,616,262</b>

**U.S. Department of State**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		20,342		20,342	0	20,342
ICASS		66,049		66,049	0	66,049
Management Meetings/Professional Development		204,892		204,892	0	204,892
Non-ICASS Administrative Costs		144,690		144,690	0	144,690
Staff Program Travel		270,231		270,231	0	270,231
USG Staff Salaries and Benefits - Internationally Recruited		540,000		540,000	0	540,000
USG Staff Salaries and		254,650		254,650	0	254,650



Benefits - Locally Recruited						
<b>Total</b>	<b>0</b>	<b>1,500,854</b>	<b>0</b>	<b>1,500,854</b>	<b>0</b>	<b>1,500,854</b>

**U.S. Peace Corps**

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		5,200		5,200	0	5,200
Management Meetings/Profes sional Development		5,390		5,390	0	5,390
Non-ICASS Administrative Costs		145,500		145,500	0	145,500
Peace Corps Volunteer Costs		1,730,010		1,730,010	0	1,730,010
Staff Program Travel		20,700		20,700	0	20,700
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits -		293,200		293,200	0	293,200

Approved



Locally Recruited						
<b>Total</b>	<b>0</b>	<b>2,200,000</b>	<b>0</b>	<b>2,200,000</b>	<b>0</b>	<b>2,200,000</b>